CA1341206C - Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them - Google Patents

Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them Download PDF

Info

Publication number
CA1341206C
CA1341206C CA000388336A CA388336A CA1341206C CA 1341206 C CA1341206 C CA 1341206C CA 000388336 A CA000388336 A CA 000388336A CA 388336 A CA388336 A CA 388336A CA 1341206 C CA1341206 C CA 1341206C
Authority
CA
Canada
Prior art keywords
alanyl
carboxylic acid
phenylpropyl
carboethoxy
azaspiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000388336A
Other languages
French (fr)
Inventor
Bernard R. Neustadt
Elijah H. Gold
Elizabeth M. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26895254&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1341206(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of CA1341206C publication Critical patent/CA1341206C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them.

Disclosed are novel carboxyalkyl dipeptides which are useful as inhibitors of angiotensinconverting enzyme and as antihypertensive agents, having the formula (see formula I) and the pharmaceutically acceptable salts thereof, wherein R and R6 are for example hydroxy, lower alkoxy or aryllower-alkoxy;
R1 is for example hydrogen, alkyl, lower alkoxy or aryloxy; R2 and R7 are the same or different and are hydrogen or lower alkyl; R3 is for example lower alkyl or phenyl lower alkyl; R4 and R5 are selected from hydrogen, lower alkyl and 2, or R4 and R5 taken together form a group represented by Q, U, V, Y, D or E wherein Z is wherein X1 and X2 independent of each other are O, S or CH2, R8 and R9 independent of each other are lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl having 3 to 8 carbon atoms, hydroxy lower alkyl or -(CH2)n Ar, wherein n is 0, 1, 2 or 3 or R8 and R9 taken together form a bridge W, wherein W is a single bond or a methylene bridge or a substituted methylene bridge when at least one of X1 and X2 is methylene, or W is an alkylene or substituted alkylene bridge having 2 or 3 carbon atoms; with the proviso that at least one of R4 and R5 is Z;

Q is V is U is wherein X1, X2 and W are as defined above;

Y is wherein G is oxygen, sulfur or CH2;

D is wherein F is O or S;

E is wherein L is O or S.

The compounds can be prepared according to known methods such as for example by condensation of an aminoacid XXI with an aminoacid XVII

Description

134120 6 ' - 1 - ~
Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them.
The present invention relates to carboxyalkyl dipeptides which are useful as inhibitors of angiotensin-converting enzyme and as antihypertensive agents.
The compounds of the present invention are com-pounds of the formula R-C- -NH-CH-C-1~1-C-C-R
~7 I
and the pharmaceutically acceptable salts thereof, wherein R and R6 are the same or different and are hydroxy, lower alkoxy, lower alkenyloxy, dilower alkylamino lower alkoxy (e. g. dimethylaminoethoxy), acylamino lower alkoxy ~-(e.g. acetylaminoethoxy), acyloxy lower alkoxy (e. g.
pivaloyloxyethoxy), aryloxy (e. g. phenoxy), arylloweralkoxy (e~g- benzyloxy), amino, lower alkylamino, dilower alkyl-'134120 6 _ 2 _ amino, hydroxyamino,aryllower alkylamino (e. g. benzylamino), or substituted aryloxy or substituted aryllower alkoxy wherein the substituent is methyl, halo or methoxy; R1 is hydrogen, alkyl of from 1 to 10 carbon atoms, including branched and cyclic and unsaturated (e. g. allyl) alkyl groups, substituted lower alkyl wherein the substituent is hydroxy, lower alkoxy, aryloxy (e. g. phenoxy), substituted aryloxy, heteroaryloxy, substituted heteroaryloxy, amino, lower alkylamino, diloweralkylamino, acylamino, arylamino, substituted arylamino, guanidino, imidazolyl, indolyl, lower alkylthio, arylthio (e. g. phenylthio), substituted arylthio, carboxy, carbamoyl, lower alkoxycarbonyl, aryl (e. g. phenyl or naphthyl), substututed aryl, aralkyloxy, substituted aral-kyloxy, aralkylthio, or substituted aralkylthio, wherein the aryl or heteroaryl portion of said substituted aryloxy, he-teroaryloxy, arylamino, arylthio, aryl, aralkyloxy or aral-kylthio groups is substituted with a group selected from w' halo, loweralkyl, hydroxy, lower alkoxy, amino, aminomethyl, carboxyl, cyano and sulfamoyl; R2 and R~ are the same or different and are hydrogen or lower alkyl; R3 is hydrogen, lower alkyl, phenyl lower alkyl, aminomethylphenyl lower alkyl, hydroxyphenyl lower alkyl, hydroxy lower alkyl, acyl-amino lower alkyl (e. g, benzoylamino lower alkyl car acetylamino lower alkyl), amino lower alkyl, dimethylamino lower alkyl, guanidino lower alkyl, imidazolyl lower alkyl, indolyl lower alkyl, or lower alkylthio lower alkyl; R4 and RSare selected from hydrogen, lower alkyl and Z, or R4 and R5 taken to-gether form a group represented by Q, U, V, Y, D or E
wherein;
Z is R8 Xl 2R9 ~~H2) I P
wherein Xl and X2 independent of each other are O, S or CH2, R8 and R9 independent of each other are lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl having 3 to 8 carbon atoms, hydroxy lower alkyl or -(CH2)nAr, wherein n is O, l, 2 or 3 and Ar is unsubstituted or substituted phenyl, furyl, thienyl or pyridil, wherein said substituted phenyl, furyl, thienyl or pyridyl groups are substituted with at least one group that is independently selected from Cl to C4 alkyl, lower alkoxy, lower alkylthio, halo, CF3 and hydroxy, or R8 and R9 taken together form a bridge W, where-in W is a single bond or a methylene bridge or a substituted methylene bridge iahen at least one of X1 and X2 is methylene, or W is an alkylene or substituted alkylene bridge having 2 or 3 carbon atoms, said substituted methylene bridge or said substituted alkylene bridge having one or two substi-__ tuents selected from lower alkyl, aryl, and aryl lower alkyl 134120 6 ' groups, and p is O, 1 or 2; with the proviso that at least one of R4 and R5 is Z, with the proviso that if R4 is Z
and p is O then X1 and X2 must both be methylene, and with the proviso that if X1 and X2 are both methylene then R$
and R9 must form an alkylene bridge W;
Q is Rg X1 X2 R9 (CH~)p (CH2)q wherein R8, R9, X1 and X2 are as defined above, p is 0, 1 or 2, q is O, 1 or 2, with the proviso that the sum of p and q must be l, 2 or 3, with the proviso that if p is O then X1 and XZ must be methylene, and with the proviso that if X1 and X2 are methylene then R8 and R9 taken to-gether form a bridge W, wherein W is as defined above;
V is R$ X 1 X2 R9 (CH2)P (CH2)q _ 5 _ 134120 6 wherein R , R9, Xl and X2 are as defined above, p is O, 1 or 2 and q is O, 1 or 2, with the proviso that the sum of p and q is 1, 2 or 3, with thw proviso that if X1 and X2 are CH2 then R$ and R9 taken together form a bridge W, wherein W is as defined above;
U is X 1~ W~.. 2 x ~CH2 p ~~CH~) wherein W is as defined above (except that W may also be a methylene bridge when Xl and X2 are oxygen or sulfur), Xl and X2 are as defined above, p is O, 1 or 2, q is O, 1 or 2, with the proviso that the sum of p and q is 1 or 2, and with the proviso that if p is O, Xl must be CH2;
Y is G
~CH~)a ~CH2)b wherein G is oxygen, sulfur or CH2, a is 2, 3 or 4 and b is 1, 2, 3, 4 or 5, with the proviso that the sum of a a and b is 5 , 6 or 7 , or ~34~zo ~ .
_ 6 _ G is CH2, a is O, l, 2 or 3 and b is O, 1, 2 or 3 with the proviso that the sum of a and b is l, 2 or 3, with the proviso that the sum of a and b may be 1, 2 or 3 only if Rl is lower alkyl substituted with aralkylthio or aralkyloxy (that is, the group Y may be a 2, 3 or 4 carbon chain only when Rl is lower alkyl substituted with aralkylthio or aral-kyloxy);
D is /F ~ ' (C/H2)~ CH2)t (CHz)~ lCH2)k 1.0 wherein F is O or S, j is O, 1 or 2, k is O, 1 or 2, with the proviso that the sum of j and k must be l, 2 or 3, and m is 1, 2 or 3 and t is 1, 2 or 3, with the proviso that the sum of m and t must be 2, 3 or 4;
E is L
\\
v CH ) (CH2)n ( s (CHZ)u (CH2)v _ ~3~~ZO s wherein L is O or S, a is O, 1 or 2, v is O, 1 or 2, with the proviso that the sum of a and v must be 1 or 2, and h is 1 or 2 and s is 1 or 2, with the proviso that the sum of h and s must be 2 or 3.
As will be seen from the above descriptions of the compounds of the present invention, when R4 and R5 form a group Q, U, V, Y, D or E, these groups, taken to-gether with the nitrogen to which R4 is attached and the carbon to which R5 is attached, form various ring systems.
Included among these ring systems are the following:
R8 1 X289 R8 X1 X2 Rg (C 2)p (GH~)q (CH2 p (CH2)q - N - C -i _N_I_ W' 1 2 /G\
(CH2)a ,CH2)b (CH2)p (CH2)Q _ N _ C _ I
- N - C -I

1341206 ' _8_ F L
(CH2)m ~CH2)t (CH~ (CH2) h s (CH~)x (CH2) a (CH2)~
_ N _ ~ _ _N _ The aforementioned groups R$ and R9, appearing in~
the groups Z, Q and V, may also form ring systems. Thus, for example when R$ and R9 in the group Z form a bridge W, as described above, the following ring system is formed:
W
x2 (CH2) When R8 and R9 in the group Q form a bridge W, as described above, the following ring system is formed:
W
gl x2 (CH2)p (CH2)Q
- N - C -i When R8 and R9 in the group V form a bridge W, as described above, the following ring system is formed:

~3~~zos, / H ,\
x 1 x2 (cH~)p (cH~)q - N _ ~ _ Each of the rings in the structures shown above will have at least four members. The values of p, q, m, t, j, k, h, s, n and v and the chosen definition of W in the rings drawn above will determine whether any of the afore-said rings will have 5 or 6 or more members.
Thus, one embodiment of the present invention com-prises compounds of the formula-I, wherein R4 and R5 are selected from hydrogen, lower alkyl and Z, wherein Z, R, Rl, R2, R3, R6 and R~ are as defined above; especially com-pounds wherein one of R4 and R5 is Z, and the other of R4 and R5 is hydrogen or lower alkyl. Among these compounds cer-taro groups of compounds can be emphasized:
.) compounds wherein Xl and X2 are methylene, R$ and R9 taken together form W, and p and W are as defined above, especially those wherein p iszero;
.) compounds wherein Xl and X2 are methylene, p is O or 1, and R8 and R9 ,taken together form an alkylene bridge having 3 carbon atoms;

- to - 134120 6 _ .) compounds wherein Xl and X2 are S, and R8, R9, and p are as defined above, especially those wherein p is 1 and R8 and R9 taken together form W, wherein W is as defined above, preferably is an alkylene bridge having 3 carbon atoms;
.) compounds wherein Xl and X2 are O, R8 and R9 are lower alkyl and p is as defined above.
Another embodiment of the present invention com-prises compounds of the formula R8 x 1 7~ R9 o Rl R3 ( ~H2)p I C N ~,-~ I~ R6 _I I I
R C C NH CH
I

8 9 1 2 and are as defined above for -wherein R , R , X , X , p q the group Q and wherein R, Rl, R2, R3, R6 and R~ are as defined above.
Non-limiting examples of compounds of the formula III are .) compounds wherein X1 and X2 are methylene, R8 and R9 taken together form the bridge W, and p, q, and W are as defined above, especially wherein W is an ethylene bridge;
wherein p and q are each 1, or ~34~~os .

wherein p is 0 and q is 2;
.) compounds, wherein Xl and X2 are S, and R8, R9, p and q are as defined above, especially compounds wherein R8 and R9 taken together form an ethylene bridge and p and q are as defined above, preferably are earch 1 or p is 1 and q is 2.
Another embodiment of the present invention com-prises compounds of the formula R8 Xl _ ,X2 R9 0 Rl R (CH2)p (CHz)q 0 R2 R ~
wherein R8, R9, Xl, X2, p and q are as defined above for the group V and wherein R, R1, R2, R3, R6 and R~ are as defined above.
Another embodiment of the present invention com-prises compounds of the formula 0 R 1 R'~ ( Hz) (CHz) 0 g I~
R CI C NH CH C N C C R~ VI
2 Fc?
R

134120 ~

wherein X1, X2, W, p and q are as defined above for the group U and R, Rl, R2, R3, R6 and R~ are as defined above.
Non-limiting examples of~compounds of the formula VI are .) compounds, wherein X1 and X2 are methylene and W is methylene and p and q are as defined above, especially wherein p is O and q is 1 and wherein p is O and q is 2;
.) compounds, wherein X1 and X2 are methylene and W is lO ethylene and p and q are as defined above, especially wherein p is O and q is 1, wherein p is 1 and q is O and wherein p is O and q is 2;
.) compounds wherein X1 and X2 are methylene and v~ is tri-methylene and p and q are as defined above, especially wherein p is O and q is 1;
.) compounds wherein X1 and X2 are methylene and W is methylene, ethylene or trimethylene substituted with one or two lower alkyl groups and p and q are as defined above, especially wherein p is O and q is 1;
.) compounds, wherein X1 and X2 are O, W is methylene and p and q are as defined above.
Another embodiment of the present invention com-prises compounds of the formula 13412~ 6 3 G
Rl ~3 ~C~~)a tCH2)b R-~-C-NH-CH- -~N / ~ R6 IX
R 2 ~ . ~7 wherein G, a and b are as defined above for the goup Y and R, Rl, R2, R3 R6 and R~ are as defined above.
Non-limiting examples of compounds of the formula IX are .) compounds wherein G is oxygen or sulfur, a is 2, 3 or 4 and b is 1, 2, 3,. 4 or 5, with the proviso that the sum of a and b is 5, 6 or 7, especially 5;
~) compounds wherein G is CH2, a is 2, 3 or 4 and b is 1, 2, 3, 4 or 5, with the proviso that the sum of a and b is 5, 6 or 7, preferably 5;
.) compounds wherein G is CH2, a is O, 1, 2 or 3, b is O, 1, 2 or 3 with the proviso that the sum of a and b is ~,2 or 3, with the proviso that the sum of a and b may bel, 2 or 3 only if Rl is lower alkyl substituted with aralkylthio or aralkyloxy, the sum of a and b preferably being 2.
Another embodiment of the present invention com-prises compounds of the formula - 14 - 134120 6 ~' /F
~ CH/Z )m H2 ) t R R3 t 2)~ H2)k ~ 1 I XI
R ' C - ~ - NH - CH - _ N _ - I~ - R6 wherein F, m, t, j and k are as defined above for the group D and R, Rl, R2, R3, R6 and R~ are as defined above. The spiro group preferably is derived from spirononane or spirodecane, especially from spiro [4.4]nonane or spiro-[4.5] decane.
Another embodiment of the present invention com-prises compounds of the formula L
H2)h ~CHZ)S
~CHZ)u ~CH2)~
R - ~ - C - NH - CH - - N - - ~ - R XII
I ~~
R
wherein L, h, s, a and v are as defined above for the group E and R, Rl, R2, R~, R6 and R~ are as defined above, the fused-ring group preferably being heXahydrofuro[3,4-b]-pyrrole-, -hexahydrothieno[3,4-b]pyrrole, octahydropyrano-134120 6 ' [3,4-b}pyrrole or -octahynrot~.iopyrano[3,4-b]pyrrole-.
In the above described compounds R, R1, R2, R3, R6 and R~ can be exemplified as follows:
.) Rl is substituted lower alkyl, wherein the substutuent is unsubstituted or lower-alkyl-substituted aryl, aralkyl-oxy or aralkylthio, in particular Rl is substituted lower alkyl, wherein the substituent is aralkyloxy or aralkylthio, especially benzyloxy or benzylthio;
.) R and R6 are the same or different and are hydroxy or lower alkoxy, especially R is hydroxy, methoxy or ethoxy and R6 is hydroxy, ethoxy or benzyloxy;
.) R2 and R~ are hydrogen;
.) R3 is hydrogen, lower alkyl or phenyl lower alkyl, expecially hydrogen, methyl or benzyl.

134120 fi - lSa -More particularly, embodiments of the present invention comprise compounds having the general formula O R~ COOR2 wherein:
Y is selected from:

C ~~-S

N-\/COOR4 N,--N -N-wherein R4 is selected from hydrogen and C1_4 alkyl Rl is selected from:

134120 6 ' - 15b -C1_4 alkyl which may be substituted with amino;
Rz is selected from:
hydrogen; and C1_4 alkyl;
R3 is selected from:
phenyl - C1_3 alkyl ; and (CHz) 1_2 - X - C1_4 alkyl wherein X is S or NH
and their pharmaceutically acceptable salts.
In addition, embodiments of the present invention also comprise compounds having the general formula O R~ COOR2 H

- 15c -wherein:
Y is selected from:

C ~C~-S

N-\/COOR4 Nl-N-wherein R4 is selected from hydrogen and C1_4 alkyl R1 is selected from:
C1_4 alkyl which may be substituted with amino;
Rz is selected from:
hydrogen; and C1_4 alkyl ;
R3 is selected from:
C1_9 alkyl ;
phenyl - C1_3 alkyl ; and (CHz) 1_z - X - C1_4 alkyl wherein X is S or NH
and their pharmaceutically acceptable salts.

..".. 13420 6 - lSd -Preferred subclasses of the present invention are aminoacyl-azabicycloalkane carboxylic acids, more prefer-ably alanyl azabicycloalkane carboxylic acids and most pre-ferably N-(alkoxycarbonyl alkylalanyl)-azabicycloalkane carboxylic acids. Aminoacylazabicycloalkane carboxylic acids that are particularly preferred are compounds of the formula ~1 ~3 ~ 6 R-C-R-NH-CH-~-N-R7C-R
VII .

134120 6 ' Alanyl-azabicycloalkane carboxylic acids of the formula VII
are more preferred and N-(alkoxycarbonylalkylalanyl)-aza-bicycloalkane carboxylic acids of the formula VII are most preferred.
Other preferred subclasses of the present inven-tion are N-(alkoxycarbonyl-aralkyloxyalkyl) dipeptides and N-alkoxycarbonyl-aralkylthio-alkyl) dipeptides. Particular-ly preferred Ore - N-(alkoxy-carbonyl-aralkylthioalkyl)-alanyl aminoacids', and most preferred are N-(alkoxycarbonyl-aralkylthioalkyl)-alanyl azacycloalkane carboxylic acids and the corresponding azabicycloalkane carboxylic acids.
The aforementioned compounds of the formula I, as defined above, include all possible stereoisomers. Acyl includes -OC-R12, wherein R12 is lower alkyl, lower alkenyl or aryl. The lower alkyl, lower alkenyl or lower alkynyl -groups except where noted otherwise are represented by any of the variables including straight and branched chain hydrocarbon radicals from one to six carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, hexyl or vinyl, allyl, butenyl and the like. Cycloalkyl groups (containing 3 to 8 carbon atoms) include bridged and non-bridged groups. The aralkyl groups represented by any of the above variables have from one to four carbon atoms in the alkyl portion thereof and - l~ - 134120 fi include for example, benzyl, p-methoxybenzyl and the like.
Halo means chloro, bromo, iodo or fluoro. Aryl where it appears in any of the radicals except where noted otherwise represents phenyl or naphthyl. Heteroaryl groups where they appear include for example pyridyl, thienyl, furyl, indolyl, benzthienyl, imidazolyl and thiazolyl. The Rl and R3 sub-stituted lower alkyl moieties are exemplified by groups such as N ~ ~N~
H
HO-CH2-, HS-CH2-, H2N-(CH2)4-. CH3-S-(CH2)2-, H2N-(CH2)3-, NH
H2N-C -NH-(CH2)3 ' In the compounds of the formula I, the carbon atoms to which R1, R3 and R5 are attached may be_asymmetric.
The compounds accordingly exist in disastereoisomeric forms .L5 or in mixtures thereof.
In general, the aminoacid part-structures, i.e., R-C-C-NH- , -NH-CHCO- and -N-C~ -C-~ 2 R7 R
of Formula I are preferred in the configuration most similar to that of natural L-amino acids. Usually, natural L-amino - 18 - ~3~~2o s acids are assigned the S-configuration. A notable exception is the natural amino acid L-cysteine which is assigned the R-configuaration.
The compounds of the present invention can be produced by one or more of the methods and subroutes depic-ted in the following equations. Reactive groups not in-volved in the condensations described below such as amino, carboxy, mercapto, etc., may be protected by'methods stand-and in peptide chemistry prior to the coupling reactions and :LO subsequently deprotected to obtain the desired products. In other words, in the formula of the following description of the processes R, Rl, R2, R3, R4, R5, R6 and R~ are as de-fined above for Formula I, including suitable protection.
A. For the preparation of compounds of formula I, wherein R2 is hydrogen a ketocompound (XIII) is condensed with a dipeptide (XIV) under reduction.

R-C-~ = O + H2NCHC-N~-C-C-R6 redu~g R~ agent XIII XIV
The ketocompound (XIII) can be condensed with the dipeptide (XIV) in aqueous solution, optimally near neutrality, or in a suitable organic solvent (for example, CH30H) in ~he presence of a reducing agent such as for example sodium _ 19 - 134~1~0 6~
cyanoborohydride to give directly the desired compound I.
Alternatively, the intermediate Schiff base, enamine, or aminol may be catalytically reduced to yield product I, for example, by hydrogen in the presence of palladium on car-bon (e.g. 10~ palladium on carbon) or of Raney nickel. The ratio of diasteriomeric products formed may be altered by choice of catalyst.
B. Alkylation of a dipeptide (XIV) by means of a compound XXII
~23 0 R4 ~R5 1 H2N-CH-C-N-C-CORE + X-C-COR ''I
R~ R2 XIV XXII
wherein X is chloro, bromo, iodo, alkanesulfonyloxy or arenesulfonyloxy. The reaction can be carried out under basic conditions in water or in an organic solvent.
C. Condensation of an amino compound (XVIII) with a keto-1.5 compound (XIX) R-C-C1NH + O=C~3O-N~4 C5C0-R6 I
R2 , 2 R7 -XVIII XIX
under the conditions described for process A.

~34~2o s Y

D. Alkylation of an aminocompound (XVIII) by means of a compound XXIII.

_ _ R O R
R C ~2 NHZ + X-CH-~-~-~-COR6 -----~ I

XVIII XXIII
wherein X is chloro, bromo, iodo, alkanesulfonyloxy or arenesulfonyloxy. The reaction can be carried out under the conditions described for process B.
F'. Condensation of an aminoacid XXI with an aminoacid XVII
O Rl 3 R4 R5 R~-C-NH~H-COOH + HN~-~-CO-R6 --~ I
P,2 R~
XXI XVII
This reaction is well known from peptide chemistry. The reaction can be carried out in the presence of a condensing agent such as for example dicyclohexylcarbodiumide (DCC), diphenylphcsi~horyl azide (DPPA) and N,N-disuccinimidyl car-bonate in CH3CN. While, as mentioned above, reactive groups (in R, R1, R3, R4, R5 and R6)are protected before the coupling reactio:~ is carried out, the amino group of compound XVII can be activated, e.g. by means of tetraethyldiphosphit and/or the carboxy group of compound XXI can be activated via the interme3iacy of active esters such as that derived from 1-hydroxybenzotriazole, its mixed anhydride (derived from a chlorocarbonic acid ester), its azide or dicyclohexyl-carbodiimide.
The starting compounds in this reaction are known compounds and/or can be prepared according to known methods.
The compound of formula XXI, wherein R2 is hydrogen can for exam,~le be prepared by reacting a keto compound XIII with an amino acid XV

R-C-C=O + H2NCH-OOH ---~ XXI
according to the conditions described in process A. Alter-natively compound XXI can be prepared by condensing XVIII
with a ketoacid XX

R-C-C-NH2 + O=C-COOH -~ XXI
~2 R
XVIII XX
or by condensing X'V and XXII or XVIII and XXIV
R3 Rl H2N-CH-COOH + X-C-COR --~. XXI
~2 R
XV XXII
~1 R3 i RCO - C -NH2 + X-CH-COOH ---~ XXI
~2 R
XVIII XXIV
under the conditions described for process B above (X being as defined in process B).

- 22 - ~3~~ao~
It is evident that a compound of formula I obtained by any one of processes A to E can be transformed into another compound of formula I by methods known in the art.
The above processes are followed by setting free protected groups by known methods. Protected carboxy groups, e.g, when R and R6 are for example alkoxy(methoxy, ethoxy, tent.
butyloxy), nitrobenzyloxy or benzyloxy, -are set free by hydrolysis or hydrogenation.(Reductive cleavage of a benzyl ester I (where R6 is benzyloxy and R is alkoxy) will yield compounds of formula I wherein R is alkoxy and R6 is hydroxy, and where R6 is alkoxy and R is benzyloxy, will yield com-pounds of formula I wherein R is hydroxy and R6 is alkoxy.) Hydrol~rsis can be carried out under acidic conditions ' (using e.g. a halogen hydracid or trifluoroacetic acid), 1.5 under basic conditions or by means of photochemical hydro-lysis.
The amino groups) can be protected by protecting groups such as for example formyl, t-butoxycarbonyl, carbobenzyl-oxy, triphenylmethyl. and nitrophenylsulfenyl. These groups can be removed under acidic conditions, e.g. by means of a halogenhydroacid and/or trifluoroacetic acid.
In the special case of Rl bearing an alpha-amino substituent, the carbonyl and amino groups can be convenient-ly protected as a beta-lactam function. This kind of pro-tection can be removed by known methods, e.g. as described above for the hydrolysis.

~3~~2~ s In the compounds of formula I, the carbon atoms to which Rl 3 5 R and R are attached may be asymmetric. The compounds accordingly exist in disastereoisomeric forms or in mix-tures thereof. The above described syntheses can utilize racemates, enantiomers or diastereomers as starting ma-terials. Enantiomeric intermediates may be obtained by resolution methods known in the art. When diastereomeric products result from the synthetic procedures, the diastereomeric products can be separated by conventional chromatographic or fractional crystallization methods.
The compounds of this invention form salts with various inorganic and organic acids and bases which are also within the scope of the invention. Such salts include am-monium salts, alkali metal salts like sodium and potassium salts (which are preferred), alkaline earth metal salts like the calcium and magnesium salts, salts with organic bases e.c~., dicyclohexylamine salts, N-methyl-D-glucamine, salts with amino acids like arginine, lysine and the like. Also, salts with organic and inorganic acids may be prepared, e.g., HCl, HBr, H2S04, H3P04, methanesulfonic acid, toluensulfonic acid, malefic acid, fumaric acid and camphorsulfonic acid. The non-toxic physiologically acceptable salts are preferred, although other salts are also useful, e.g., in isolating or purifying the product.

The salts may be formed by conventional means, as by reac-ting the free acid or free base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging the cations of an exis-ting salt for another cation on a suitable ior. e:~c~,.ange resin.
The compounds of this invention have useful phar-macological properties. They are useful in the treatment of high blood pressure.
The compounds of the present invention can be 1.0 combined with pharmaceutical carriers and administered in a variety of well known pharmaceutical forms suitable for oral or parentet-aJ. administration to provide compositions useful in the treatment of cardiovascular disorders and particularly mammalian hypertension.
The dosage of the compounds of this invention will typically be in the range of about O.O1 to about 30 mg/kg, preferably about 0.1 to about 10 mg/kg, of mammalia weight, administered in single or divided doses.
The exact dose to be administered is dependent upon where the particular. compound lies within the above quoted range, as well as upon the age, weight and condition of the indivi-dual.

- 25 - ~3~~2os Generally, in treating humans, the compounds of this in-vention may be administered to patients in need of such treatment in a dosage range of 5 to 500 mg per patient generally given several times, thus giving a total daily dose of from 5 to 2000 mg per day. Also, the compounds of this invention may be given in combination with diu-retics or other antihypertensives. Typically, these are combinations whose individual dosages range from one-fifth of the minimally recommended clinical dosages to the maxi-mum recommended levels for the entities when they are given singly. Examples of such diuretics or other antihyperten-sives are hydrochlorothiazide, ethacrynic acid, amiloride, furosemide, propanolol, timolol ; ~methyldopa.and chloro-thiazide.
The composition containing the compounds of this 1.5 invention will preferably contain from about 5 to about 250 mg of the active compound per dosage unit. These compo-sitions are most preferably administered orally. Typical formulations for oral administration are those such as tablets, capsules, syrups, elixirs or suspensions. Typical injectable formulations include solutions and suspensions.
Typical acceptable pharmaceutical carriers for use in the formulations described above are exemplified by:
sugars such as lactose, sucrose, mannitol and sorbitol;
starches such as corn starch, tapioca starch and potato - 26 - ~3~~zo s starch; cellulose and derivatives such as sodium carboxy-methyl cellulose, ethyl cellulose and methyl cellulose;
calcium phosphates such as dicalcium phosphate and tri-calcium phosphate; sodium sulfate; calcium sulfate, poly-vinylpyrrolidone, polyvinyl alcohol; stearic acid; alkaline earth metal stearates such as magnesium stearate and calcium stearate, stearic acid~vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil and corn oil; non-ionic, cationic and anionic surfactants; ethylene glycol polymers; beta-cyclodextrin; fatty alcohols and hydrolyzed cereal solids; as well as other non-toxic compatible fillers, binders, disintegrants, buffers, preservatives, antioxidants, lubricants, flavoring agents, and the like commonly used in pharmaceutical formulations.
7_5 The following examples illustrate the preparation of the compounds of the present invention. The diasteromers prepared as setforth below may be isolated by column chroma-tography or by fractional crystallization.
In the examples below, octahydroindole-2(S)-car-boxylic acid refers to cis, syn-octahydroindole-2(S)-car-bo;cylic acid, also named 3a(S), 7a(S)-octahydroindole-2(S)-carboxylic acid.

-27- 1341206'"
Example 1 1-[N-(1-Carbomethoxy-3-phenylpropyl)-(S)-alanyl]octahydro-indole-2(S)-carboxylic acid A. Dissolve 27.0 g of ethyl indole-2-carboxylate in 250 ml of trifluoroacetic acid. Add 2.05 g of platinium oxide, hydrogenate the mixture at 50 lb/in2 at room tempe-rature. Filter the mixture and concentrate the filtrate in vacuo to give a residue. Suspend the residue in ether and treat with cold dilute sodium hydroxide solution. Dry the 1.0 organic layer dried over magnesium sulfate and concentrate it to give ethyl octahydroindole-2-carboxylate, a pale yel-low oil. The oil should immediately be used in the following step.
To a solution of 10.0 g of ethyl octahydroindole-2-carboxylate (prepared in as shown in paragraph A of this example) in 400 ml of ethyl acetate add 17.0 g of N-benzyl-oxycarbonyl-(S)-alanine, N-hydroxysuccinimide ester. Stir the reaction mixture at room temperature for 20 hours and concentrate it in vacuo. Place the residue on a column of silica gel (3000 g, 60-200 mesh) and elute with chloroform:
ethyl acetate 10:1 to give 1-[N-benzyloxycarbonyl-(S)-alanyl]-octahydroindole-2(R)-carboxylic acid, ethyl ester, a colorless oil [a]D26 + 22.0° (ethanol) and 1-[N-benzyloxy-carbonyl-(S)-alanyl]octahydroindole-2(S)-carboxylic acid, ethyl ester, a colorless oil [a]D26 -96.4° (ethanol).

- 2g - 134120 6 C. To a solution of 3.22 g of 1-[N-benzyloxycarbonyl-(S)-alanyl]octahydroindole-2(S)-carboxylic acid, ethyl ester in 150 ml of methanol, add 20 rnl of 2.5 N sodium hydroxide and stir the mixture at room temperature for 18 hours. Concentrate the mixture under nitrogen, dilute the residue with ice-water and then make the mixture acidic with concentrated hydrochloric acid. Extract the aqueous so-lution with ethyl acetate and dry the organic phase over magnesium sulfate. Concentrate the organic phase and place :LO it on a column of silica gel (500 g., 60-200 mesh). Elute with chloroform:glacial acetic acid 9:1 to give 1-[N-benzyloxycarbonyl-(S)-alanyl]octahydroindole-2(S)-carboxy-lic acid, a white solid [a]D26 - 62.1° (ethanol), m.p.
58.60°.
D. Dissolve 1.70 g of 1-[N-Benzyloxycarbonyl-(S)-alanyl]-octahydroindole-2(S)-carboxylic acid in 100 ml of methanol.
Add 0.40 g 10~ palladium-on charcoal and hydrogenate the mixture at atmospheric pressure. Filter the mixture and concentrate in vacuo to give 1-[(S)-alanyl]octahydroindole-2(S)-carboxylic acid, a white solid [a]D26 -18.5° (ethanol), m.p. 163-165°.
E. Dissolve 1-[(S)-alanyl]octahydroindole-2(S)-carboxy-lic acid (prepared in paragraph D of this example) in 100 ml of absolute methanol. Add 1.10 g 2-oxo-4-phenylbutyric acid, X34120 ~

ethyl ester and 20 ml of 3 Angstrom molecular sieve pel-lets, and stir the resulting mixture at room temperature for eighteen hours. Filter the reaction mixture and treat the filtrate with 0.68 g sodium cyanoborohydride at room temperature for two hours. Concentrate the mixture under nitrogen and dilute the oil with dilute hydrochloric acid and stir at room temperature for one hour. Absorb the aqueous solution on 200 ml of a XAD-2 (Rohm & Haas Co.
resin). Elute the resin with 2000 ml of water and then with 2000 ml of methanol. Concentrate the methanol solution and place the residue an a column of silica gel (400 g, 60-200 mesh) and elute with chloroform:isopropanol: 7$ ammonium hydroxide l: 1: 1 (organic layer) to give 1[r~1(1-methoxycarbonyl-3-phenylpropyl)-(S)-alanyl]octahydroindole-2(S)-carboxylic acid, a white solid [a]D26 _45.2° (ethanol), m.p. 71-73°.
Example 2 1-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]octahydroindole-2(S)-carboxylic acid To a solution of 1-[N-(1-carbomethoxy-3-phenylpropyl)-(S)-alanyl]octahydroindole-2(S)-carboxylic acid (prepared as described in Example 1) in methanol, add 2.5 N sodium hydro-xide. After three hours, concentrate the reaction mixture and absorb it on an XAD-2 resin column and elute with water and then with methanol. Concentrate the methanol eluant to 134120 fi give a residue and absorb this residue on a silica gel column and elute with chlorform:methanol: 14~ ammonium hydroxide 1:1:1. Concentrate the desired eluant fractions to obtain the title compound.
Example 3 1-[N-(1-carboethoxy-3-p-chlorophenylpropyl)-(S)-alanyl]-octahydroindole-2(S)-carboxylic acid React 1-[(S)-alanyl]octahydroindole-2(S)-carboxylic acid (prepared as described in Example 1) and ethyl p-chlorophenyl-2-oxobutyrate with sodium cyanoborohydride as described in Example lE (ethanol solvent) to obtain the title compound.
Example 4 1-[N-(1-carboxy-3-p-chlorophenylpropyl)-(S)-alanyl]octa-1_'~ hydroindole-2(S)-carboxylic acid Treat the ester (prepared as described in Example 3) with sodium hydroxide in methanol as described in Example 2 to yield the title compound.
Example 5 1-[N-(1-carboxy-2-phenylethyl)-(S)-alanyl]octahydroindole-2(S)-carboxylic acid To a mixture of 1-[(S)-alanyl)octahydroindole-2(S)-carboxylic acid (prepared as described in Example 1) and phenylpyruvic acid in methanol water at a pH of about 7, at room temperature, add sodium cyanoborohydride. Upon completion of the reaction, absorb the residue on a XAD-2 resin and elute with methanol followed by further purifi-cation by elution from silica gel using chloroform: methanol:
14~ ammonium hydroxide 1:1:1 to isolate the~title compound.
Example 6 :LO 1-[N-(1-aminocarbonyl-3-phenylpropyl)-(S)-alanyl]octahydro-indole-2(S)-carboxylic acid React 1-[(S)-alanyl]octahydroindole-2(S)-carboxylic acid (preparable as described in Example 1) and 2-oxo-4-phenylbutyramide and sodium cyanoborohydride to obtain the title compound as described in Example 5. -Example 7 1-~N-[1-carboxy-3-(3-indolyl)propyl]-(S)-alanyl~octahydro-indole-2(S)-carboxylic acid Condense 1-[(S)-alanyl)octahydroindole-2(S)-carboxylic acid (preparable as described in Example 1) and 4-(3-indo-lyl)-2-oxobutyric acid with sodium cyanoborohydride, using the procedure described in Example 5) to yield the title compound.

134124 ~
_ 32 -Example 8 1-~N-[1-carboethoxy-2-(3-indolyl)ethyl]-(S)-alanylyocta-hydroindole-2(S)-carboxylic acid As described in Example 1), react 1-[(S)-alanyl]-octahydroindole-2(S)-carboxylic acid and ethyl indole-3-pyruvate with sodium cyanoborohydride to obtain the title compound.
Example 9 1-[N-(1-carboxy-2-phenoxyethyl)-(S)-alanyl]octahydroindole-lp 2(S)-carboxylic acid As described in Example 5), condense 1-[(S)-alanyl]-octahydroindole-2(S)-carboxylic acid (prepared as described in Example 1) and phenoxypyruvic acid (preparable from ethyl phenoxyacetate and diethyl oxalate, followed by acid cata-lysed hydrolysis and decarboxylation) with sodium cyanoboro-hydride to obtain the title compound.
Example 10 1-[N-(1-carboethoxy-2-phenoxyethyl)-(S)-alanyl]octahydro-indole-2(S)-carboxylic acid ?p React 1-[(S)-alanyl]octahydroindole-2(S)-carboxylic acid (preparable as described in Example 1) and ethyl phenoxypyruvate, (prepared from esterification of phenoxy-'l34i20 6 pyruvic acid as described in Example 9) with sodium cyano-borohydride as described in Example 1) to give the title compound.
Example 11 1-[N-(1-carboxy-2-phenylthioethyl)-(S)-alanyl]octahydro-indole-2(S)-carboxylic acid Condense 1-[(S)-alanyl]octahydroindole-2(S)-carboxy-lic acid (prepared as described in Example 1) and phenyl-thiopyruvic acid (preparable from ethyl phenylthioacetate and diethyl oxalate, followed by acid catalyzed hydrolysis and decarboxylation) with sodium cyanoborohydride as des-cribed in Example 5) to yield the title compound.
Example 12 1-[N-(1-carboxyethyl)-(S)-alanyl]octahydroindole-2(S)-car-boxylic acid As described in Example 5, react 1-[(S)-alanyl]-octahydroindole-2(S)-carboxylic acid (prepared as described in Example 1) and pyruvic acid with sodium cyanoborohydride to obtain the title compound.
Example 13 1-[N-(1-carboxy-2-cyclohexylethyl)-(S)-alanyl]octahydro-indole-2(S)-carboxylic acid Condense 1-[(S)-alanyl]octahydroindole-2(S)-carboxy-lic acid (prepared as described in Example 1) and 3-cyclo-hexyl-2-oxopropionic acid with sodium cyanoborohydride as described in Example 5) to obtain the title compound.
Example 14 1-[N-(1-carboxy-5-methylexyl)-(S)-alanyl]octahydroindole-2(S)-carboxylic acid To 1-[(S)-alanyl]octahydroindole-2(S)-carboxylic acid (prepared as described in Example 1) and 4-methyl-2-oxo-pentanoic acid add sodium cyanoborohydride using the pro-cedure described in Example 5) to obtain the title compound.
Example 15 1-[N-(1,3-dicarboxypropyl)-(S)-alanyl]octahydroindole-2(S)-carboxylic acid As described in Example 5), treat 1-[(S)-alanyl]-octa-hydroindole-2(S)-carboxylic acid (prepared as described in Example 1) and 2-oxoglutaric acid with sodium cyanoborohyd-ride to isolate the title compound.

Example 16 1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]decahydro-quinoline-2(S)-carboxylic acid Use ethyl decahydroquinoline-2-carboxylate (prepared by hydrogenation of quinoline-2-carboxylic acid in glacial acetic acid with platinum oxide followed by esterfication in ethanol) in place of ethyl octahydroindole-2-carboxylate in Example 1B. Continue the sequence of reactions described in Example 1) through Example lE to obtain the title com-pound.
Example 17 1-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]decahydroquino-line-2(S)-carboxylic acid As described in Example 2, treat 1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl)decahydroquinoline-2-carboxylic acid (prepared as described in Example 16) with sodium hydroxide to obtain the title compound.
Example 18 2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]octahydro-isoindole-1(S)-carboxylic acid A. Heat cis-octahydroisoindole (prepared by reduction of cis-hexahydrophthalimide in tetrahydrofuran with lithium 134120 0 , aluminum hydride) and mercuric acetate in 10$ aqueous acetic acid under reflux for twenty hours to give cis-hexahydro-Dl-isoindole. Dissolve this compound in water and treat with potassium cyanide followed by 2N hydrochlo-ric acid at 0° for two hours and at room temperature for twenty hours to give 1-cyano-cis-octahydroisoindole. Heat this cyano compound in 6N hydrochloric acid under reflux for 6 hours followed by concentration of the reaction mixture and absorption of the residue on an XAD-2 resin column.
Elute with methanol to obtain cis-octahydroisoindole-1-carboxylic acid.
B. Use ethyl cis-octahydroisoindole-1-carboxylate (pre-pared by esterification with ethanol of the acid prepared in paragraph A next above) in place of ethyl octahydro_-1~~ indole-2-carboxylate in Example 1B trough lE to give the title coumpound.
Example 19 2-[N-dl-carboxy-3-phenylpropyl)-(S)-alanyl]octahydroiso-indole-1(S)-carboxylic acid 2C' As described in Example 2 treat N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]octahydroisoindole-1(S)-carboxylic acid (prepared as described in Example 18) with sodium hydroxide to obtain the title compound.

~3412p g_ Exam; lp a 20 1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]octahydro-cyclopenta[b]pyrrole-2(S)-carboxylic acid A. Substitute octahydrocyclopenta[b]pyrrole (prepared by reduction of 2-ketooctahydrocyclopenta[b]pyrrole in tetrahydrofuran with lithium aluminum hydride) for octahydroisoindole in Example 18A to obtain octahydrocylo-penta[b]pyrrole-2-carboxylic acid.
B. Use ~hyl octahydrocyclopenta[b]pyrrole-2-carboxylate lp (prepared by esterification with the ethanol of the acid prepared as described in paragraph A) in place of ethyl octahydroindole-2-carboxylate in the procedure described in paragraphs B through E of Example 1 to give the title compound.
15 Example 21 1-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]octahydrocyclo-penta[b]pyrrole-2(S)-carboxylic acid As described in Example 2), hydrolyze the ester (pre-pared as described in Example 20) with sodium hydroxide 20 to obtain the title compound.

Example 22 5-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-2,2-dimethyl-octahydro-1,3-dioxolo[4,5-c]pyrrole-4(S)-carbo-xylic acid Heat 1-benzyloxycarbonyl-3,4-dihydroxy-(S)-proline [preparable from reaction of 3,4-dihydroxy-(S)-proline.in 2N sodium hydroxide with benzyl chloroformate in ether]
with 2,2-dimethoxy propane in dimethylformamide and p-toluenesulfonic acid to obtain 5-benzyloxycarbonyl-2,2-dimethyloctahydro-1,3-dioxolo[4.5-c]pyrrole-4(S)-carboxylic acid.
Hydrogenate this compound in methanol with palladium on carbon to give 2,2-dimethyloctahydro-1,3-dioxolo[4,5-c]-pyrrole-4(S)-carboxylic acid. React this compound with N-benzyloxycarbonyl-(S)-alanine, N-hydroxysuccinimide ester as described in Example 1B-E to isolate the title compound.
Example 23 7-[N-(~rboethQxy-3-Phenylpropyl)-(S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid A. Dissolve 7.U g of 1-benzyloxycarbonyl-4-keto-(S)-proline methyl ester in 75 ml of glacial acetic acid. Add 0.7 g of ~-toluenesulfonic acid and 2.8 g of 1,2-ethane-dithiol and heat under reflux with stirring for eighteen hours. Add the reaction mixture to saturated sodium bicar-bonate solution and extract with ethyl acetate. Dry the organic layer over magnesium sulfate and concentrate it.
Place the residue on a column of silica gel (300 g, 60-200 mesh) and elute with hexane: ethyl acetate (1:1) to give 7-benzyloxycarbonyl -1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid, methyl ester, a yellow oil having [a]D26-12.6° (dioxane).
B. Dissolve 3.0 g of 7-benzoyloxycarbonyl-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid, methyl ester in 20 ml of 20o hydrobromic acid in glacial acetic acid and stir the mixture dropwise to diethyl ether at O-5°C to give 1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid, methyl ester hydrobromide, a brown solid m.p. 156-158°.
C. Dissolve the 1,4-dithia-7-azaspiro[4.4]nonane-8(S)-1.5 carboxylic acid, methyl ester, hydrobromide from paragraph B in O.1N NaOH and extract with ethyl acetate. Dry the organic layer over magnesium sulfate and concentrate in vacuo to give 1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxy-lic acid, methyl ester (1.35 g). Dissolve the latter in 100 ml of ethyl acetate and treat with 2.07 g of N-benzyl-oxycarbonyl-(S)-alanine, N-hydroxysuccinimide ester. Stir the reaction mixture at room temperature for eighteen hours and concentrate in vacuo. Place the residue on a column of silica gel (300 g, 60-200 mesh) and elute with hexane:

ethyl acetate 4:1 to obtain 7-[N-benzyloxycarbonyl-(S)-alanyl]-1,4-dithia-7-azaspiro[4.4Jnonane-8(S)-carboxylic acid, methyl ester, a yellow oil [aJD26-14.8° (ethanol).
D. Dissolve 1.05 g of 7-[N-benzyloxycarbonyl-(S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid, methyl ester in 100 ml of methanol. Add 10 ml of 2.5N sodium hydroxide and stir the mixture at room tempe-rature for sixteen hours. Concentrate the mixture under nitrogen, dissolve the oil in O.1 N sodium hydroxide and dilute with ice water. Extract the aqueous solution with ethyl acetate. Acidify the aqueous solution with concen-trated hydrochloric acid and then extract with ethyl ace-tate. Dry the organic phase over magnesium sulfate and concentrate it. Place the residue on a column of silica gel (100 g, 60-200 mesh) and elute with chloroform: glacial acetic acid 19:1 to obtain 7-[N-benzyloxycarbonyl-(S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid, [a]D26-15.8° (ethanol).
E. Dissolve 1.4 g of 7-[N-benzyloxycarbonyl-(S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid in 20 ml of 20~ hydrobromic acid in glacial acetic acid and stir the mixture at room temperature for 2 hours. Add the mixture dropwise to diethyl ether at O-S°C to give 7-[(S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid hydrobromide which is used immediately in the pro-cess described in paragraph F below.
F. Dissolve the 7-[(S)-alanyl]-1,4-dithia-7-azaspiro-[4.4]nonane-8(S)-carboxylic acid, hydrobromide (prepared in paragraph E next above) in 100 ml of absolute methanol.
Add 0.5 g of 2-oxo-4-phenylbutyric acid, ethyl ester and ml of 3°A molecular sieve pellets and stir the mixture at room temperature for eighteen hours. Filter the reaction mixture and treat the filtrate with 0.30 g of sodium cyano-10 borohydride at room temperature for two hours. Concentrate the mixture under nitrogen and dilute the oil with 5~
hydrochloric acid to pH 2 to 4 and stir at room temperature for one hour. Adjust the pH of the solution to pH 8 with 2.5N sodium hydroxide solution and absorb the solution in 150 ml of a XAD-2 resin. Elute the resin with 800 ml of water and then with 800 ml of methanol. Concentrate the methanol solution, place the residue on a column of silica gel (100 g, 60-200 mesh) and elute with chloroform:isopro-panol: 7~ ammonium hydroxide 1:1:1 (organic layer) to ob-taro 7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid, a white solid, m.p. 56-60°C, [a] 26-25.5° (ethanol).
D

134120 6' Example 24 7[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid Hydrolize 0.18 g of 7-[N-(1-carboethoxy-3-phenylpro-pyl)-(S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid (prepared as described in Example 23) in 600 ml of methanol with 10 ml of 2.5N sodium hydroxide, concentrate the reaction mixture and absorb it on an XAD-2 resin column and elute with water and then with metha-nol. Concentrate the methanol eluant to give a residue and absorb this residue on a silica gel column (100 g, 60-200 mesh). Elute the column with chloroform:methanol: 140 ammonium hydroxide 1:1:1 and concentrate the desired eluant fractions to obtain the title compound.
1.5 Example 25 7-[N-(1-carbomethoxy-3-methylthiopropyl)-(R,S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid A. Couple 1,4-dithia-7-azaspiro[4.4]nonane-8(S)-car-boxylic acid, methyl ester (prepared as described in Example 23) with pyruvic acid using dicyclohexylcarbodi-imide and triethylamine in dioxane to yield, after iso-lation and hydrolysis of the ester, 7-pyruvoyl-1,4-dithia-7-azaspiro-[4.4]nonane-8(S)-carboxylic acid.

- 43 - ~3~~2o s B. Condense 7-pyruvoyl-1,4-dithia-7-azaspiro[4.4]-nonane-8(S)-carboxylic acid and (S)-methionine, methyl ester with sodium cyanoborohydride in methanol at pH 7 for three days at room temperature followed by chromato-graphy on a XAD-2 resin column, using methanol as eluant, to obtain the title compound.
Example 26 7-[N-(1-carboxy-3-methylthiopropyl)-(R, S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid Treat 7-[N-(1-carbomethoxy-3-methylthiopropyl)-(R,S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid (prepared as described in Example 25) with sodium hydroxide in methanol as described in Example 24) to yield the title compound.
Example 27 7-{N-[1-carbomethoxy-2-(3-indolyl)ethyl]-(R, S)-alanyl~-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid Use 7-pyruvoyl-1,4-dithia-7-azaspiro[4.4)nonane-8(S)-carboxylic acid (prepared as described in Example 25) and condense with tryptophan methyl ester in the presence of sodium cyanoborohydride using the method described in Exam-ple 25) to obtain the title compound.

- 44 - 13412~ 6 Example 28 7-tN-(1-carboxy-2-(3-indolyl)ethyl]-(R, S)-alanyl}-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid Hydrolize 7-~N-[1-carbomethoxy-2-(3-indolyl)ethyl]-(R,S)-alanyl}-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxy-lic acid (prepared as described in Example 27) with sodium hydroxide as described in Example 24) to yield the title compound.
Example 29 lp 7-tN-[ 1-carbomethoxy-2-(1H-imidazol-4-yl)ethyl]-(R,S)-alanyl}-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid As described in Example 25, react 7-pyruvoyl-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid (prepared as described in Example 25) and (S)-histidine, methyl ester in the presence of sodium cyanoborohydride to obtain the title compound.
Example 30 7-tN-[1-carboxy-2-(1H-imidazol-4-yl)ethyl]-(R, S)-alanyl}-1,4-2U dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid Treat 7-~N-[1-carbomethoxy-2-(1H-imidazolyl-4-yl)-ethyl]-(R,S)-alanyl}-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-- 45 - 13 412 p g .
carboxylic acid (prepared as described in Example 29) with sodium hydroxide.as described in Example 24) to yield the title compound.
Example 31 7-[N-(1-carboethoxy-3-phenylpropyl)glycyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)carboxylic acid A. As described in Example 23, react 1-benzyloxycar-bonyl-4-keto-(S)-proline, ethyl ester (prepared from the acid by esterification in ethanol) with 1,2-ethanedithiol to obtain 7-benzyloxycarbonyl-1,4-dithia-7-azaspiro[4.4]-nonane-8(S)-carboxylic acid, ethyl ester, a yellow oil [a]D26-21.0° (ethanol).
B. Convert 2.22 g of 7-benzyloxycarbonyl-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid, ethyl ester (pre-pared as described in paragraph A) to 1,4-dithia-7-azaspiro-[4.4]nonane-8(S)-carboxylic acid, ethyl ester as described in in Example 23 and couple this compound with 1.5 g of N-benzyloxycarbonylglycine, N-hydroxysuccinimide ester as described in Example 23) to yield 7-(N-benzyloxycarbonyl-glycyl)-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid, ethyl ester, a yellow oil [a]D26-21.0°.

- 46 - ~3~~zos..
C. Hydrolize 1.43 g of 7-(N-benzyloxycarbonylglycyl)-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid, ethyl ester (prepared as described in paragraph B next above) with sodium hydroxide as described in Example 23 to obtain 7-(N-benzyloxycarbonylglycyl)-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid, a colorless oil, [a]D26-7.9°.
D. Treat 0.95 g of the acid obtained in the process described in paragraph C next above with 20o hydrobromic 1.0 acid in glacial acetic acid as described in Example 23) to obtain 7-glycyl-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid, hydrobromide [a]D26 18.7°.
E. As described in Example 23, couple 0.76 g of 7-glycyl-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic 1.5 acid, hydrobromide (prepared as described in paragraph D
next above) with 0.50 g of 2-oxo-4-phenylbutyric acid, ethyl ester to obtain 7-[N-(1-carboethoxy-3-phenylpropyl)-glycyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid.
2p Example 32 7-[N-(1-carboxy-3-phenylpropyl)glycyl]-1,4-dithia-7-azas-piro[4.4]nonane-8(S)-carboxylic acid As described in Example 24, hydrolize 7-[N-(1-carbo-ethoxy-3-phenylpropyl)glycyl]-1,4-dithia-7-azaspiro[4.4]-nonane-8(S)-carboxylic acid (prepared as described in Example 31) with sodium hydroxide to give the title com-pound.
Example 33 7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1,4-dithia-7-azaspiro[4.5]decane-8(S)-carboxylic acid A. Dissolve 1-benzyloxycarbonyl-5-hydroxy-(S)-pipeco-lp lic acid(prepared from 5-hydroxy-(S)-pipecolic acid in 2N
sodium hydroxide solution treated with benzylchlorformate in diethyl ether) in acetone and treat with Jones reagent to obtain 1-benzyloxycarbonyl-5-keto-(S)-pipecolic acid.
Then esterify in methanol to give the resprective methyl 1~, ester.
B. Substitute 1-benzyloxycarbonyl-5-keto-(S)-pipecolic acid, methyl ester as the keto-ester in Example 23) and follow the procedure described to obtain the title com-pound.
2a Example 34 7-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-1,4-dithia-7-azaspiro~4.5]decane-8(S)-carboxylic acid Hydrolize7 [N-(1-carlx~thoxy-3-phenylpropyl)-(S)-alanyl]-1,4-dithia-7-azaspiro[4.5]decane-8(S)-carboxylic acid (prepared as described in Example 33) with sodium hydroxide and isolate the title compound using the procedure des--cribed in Example 24.
Example 35 1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1-azaspiro-[4.4]nonane-2(S)-carboxylic acid A. Condense nitrocyclopentane (prepared from bromocyclo-pentane and sodium nitrite) and acrolein in tetrahydro-furan in the presence of sodium hydride to obtain 3-(1-nitrocyclopentyl)propionaldehyde. Treat this aldehyde with p-toluene-sulfonic acid in methanol and isolate 3-(1-nitro-cyclopentyl)propionaldehyde dimethyl acetal. Hydrogenate this compound with Raney nickel. Isolate 3-(1-aminocyclo-pentyl)propionaldehyde dimethylacetal and dissolve in aqueous acetone in the presence of p-toluenesulfonic acid and heat under reflux, followed by additon of toluene and azeotrope the mixture to give 1-azaspiro[4.4]-O1-nonane.
B. Substitute 1-azaspiro[4.4]-Dl-nonane(from paragraph A) for cis-hexahydro-Dl-isoindole in Example 18A to obtain 1-azaspiro[4.4]nonane-2-carboxylic acid.

- 49 - ~34i2o s C. Use 1-azaspiro[4.4]nonane-2-carboxylic acid, ethyl ester prepared by esterification of the acid (obtained as described in paragraph B) in methanol in place of octa-hydroindole-2-carboxylic acid, ethyl ester in Example 1B
through lE to obtain the title compound.
Example 36 2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-2-azaspiro-[4.4]nonane-3(S)-carboxylic acid A. Reduce 2-(1-cyanocyclopentylacetaldehyde diethyl acetal (preparable from 3-cyanopropionaldehyde diethyl acetal and 1,4-dibromobutane in tetrahydrofuran in the presence of sodium hydride) with lithium aluminum hydride to yield 2-(1-aminomethylcyclopentyl)acetaldehyde, diethyl acetal. Dissolve this compound in aqueous acetone in the presence of p-toluenesulfonic acid and heat under reflux, followed by addition of toluene and azeotrope the mixture to give O2-2-azaspiro[4.4]nonane.
B. Substitute OZ-2-azaspiro[4.4]nonane (prepared as described in paragraph A for cis-hexahydro-Ol-isoindole in Example 18A to yield 2-azaspiro[4.4]nonane-3-carboxylic acid.

134120 6 .

C. As described in Example 1B through lE, substitute 2-azaspiro[4.4]nonane-3-carboxylic acid, ethyl ester (pre-parable by esterfication of the acid from paragraph B in ethanol) for octahydroindole-2-carboxylic acid, ethyl ester to obtain the title compound.
Example 37 1-[N-~(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-4(R,S)-[2-(1,3-dithianyl)]-(S)-proline A. React 4(R,S)-cyano-(S)-proline, methyl ester (pre-pared from reaction of 4(R)-tosyloxy-(S)-proline, methyl ester in acetonitrile with potassium cyanide and dibenzo-18-crown-6) with 2-methyl-2,4-pentanediol in cold concen-trated sulfuric acid to yield 4-[2-(4,6,6-trimethyl-5, 6-dihydro-4H-1,3-oxazinyl)1-(S)-proline, methyl ester. Re-duce this compound with sodium borohydride in aqueous methanol at pH 2-4 at O°, and then hydrolyze with aqueous oxalic acid to yield 4-formyl-(S)-proline, methyl ester.
B. Combine 4-formyl-(S)-proline, methyl ester (pre-pared as described in paragraph A) and 1,3-propanedithiol by the procedure described in Example 23 to obtain the title compound.

- 51 - 134120 6 .
Example 38 N-[N-(1-carbomethoxy-3-phenylpropyl)-(S)-alanyl~-N-cyclohexyl-(S)-alanine Substitute N-cyclohexyl-(R, S)-alanine, ethyl ester (prepared from cyclohexylamine and ethyl bromoacetate) for ethyl octahydroindole-2-carboxylate in Example 1B and continue the sequence through to lE to obtain the title compound.
Example 39 N-~N-[(1-carbomethoxy-3-phenylpropyl)-(S)-alanyl]l-N-(2,2-diethoxy)ethyl-(S)-alanine Use N-(2,2-diethoxy)ethyl-(S)-alanine, methyl ester (prepared from (S)-alanine, methyl ester, hydrochloride and bromoacetaldehyde diethylacetal) for ethyl octahydroindole-1:5 2-carboxylate in Example 1B and continue the sequence through to lE to isolate the title compound.
Example 40 N- [N- (1-carboethoxy-3-phenylpropyl) - (S) -alanyl] -N- [2- (1, 3-dithianyl)methyl] - (S) -alanine Combine N-(2,2-diethoxy)ethyl-(S)-alanine, methyl ester (prepared as described in Example 39) and 1,3-propanedithiol as described in Example 23A and continue the sequence as outlined to yield the title compound.

Example 41 1-[N-(1-ethoxycarbonyl-3-phenylpropyl)-(S)-alanyl]azacyclo-octane-2(S)-carboxylic acid A. To a solution of 9.4 g of ethyl azacyclooctane-2-carboxylate in 400 ml of ethyl acetate add 17.0 g of N-benzyloxycarbonyl-(S)-alanine, N-hydroxysuccinimide ester.
Stir the reaction mixture at room temperature for 20 hours and concentrate it in vacuo to give 1-[N-benzyloxycarbonyl-(S)-alanyl]azacyclooctane-2(R,S)-carboxylic acid, ethyl ester, as a colorless oil.
B. To a solution of 3.09 g of 1-[N-benzyloxycarbonyl-(S)-alanyl]azacyclooctane-2(R,S)-carboxylic acid, ethyl ester in 150 ml methanol, add 20 ml of 2.5 N sodium hydro-xide and stir the mixture at room temperature for l8 hours.
Concentrate the mixture under nitrogen, dilute the residue with ice-water and then make the mixture acidic with con-centrated hydrochloric acid. Extract the aqueous solution with ethyl acetate and dry the organic phase over magnesium sulfate. Concentrate the organic phase to give a white re-sidue. Place the residue on a column of silica gel (1000 ml, 60-200 mesh) and elute with chloroform:isopropanol:7o NH40H
(organic phase to give 1-[N-benzyloxycarbonyl-(S)-alanyl]-azacyclooctane-2(R)-carboxylic acid and 1-[N-benzyloxycar-bonyl-(S)-alanyl]azacyclooctane-2(S)-carboxylic acid, as colorless oils.

C. Dissolve 1.59 g of 1-[N-benzyloxycarbonyl-(S)-alanyl]azacyclooctane-2(S)-carboxylic acid in 100 ml of methanol. Add 0.40 g 10$ palladium-on-charcoal and hydro-genate the mixture at atmospheric pressure. Filter the mixture and concentrate in vacuo to give 1-[(S)-alanyl]-azacyclooctane-2(S)-carboxylic acid.
D. Dissolve 1-[(S)-alanyl]azacyclooctane-2(S)-carbo-xylic acid (prepared in paragraph C of this example) in 100 ml of absolute ethanol. Add 1.10 g 2-oxo-4-phenyl-butyric acid, ethyl ester and 20 ml of 3 Angstrom molecu-lar sieve pellets, and stir the resulting mixture at room temperature for eighteen hours. Filter the reaction mix-ture and treat the filtrate with 0.68 g sodium cyanoboro-hydride at room temperature for two hours. Concentrate the mixture under nitrogen and dilute the oil with dilute hydrochloric acid and stir at room temperature for one hour.
Absorb the aqueous solution on 200 ml of a XAD-2 (Rohm &
Hass Co.) resin. Elute the resin with 2000 ml of water and then with 2000 ml of methanol. Concentrate the methanol solution and place the residue on a column of silica gel (400 g, 60-200 mesh) and elute with chloroform:isopropanol:
7~ ammonium hydroxide l:l:l (organic layer) to give 1-[N-(1-ethoxycarbonyl-3-phenylpropyl)-(S)-alanyl]azacyclo-octane-2(S)-carboxylic acid.

~34~20 6 Example 42 1-[N-(1-carboxy-3-phenylpropyl)-(S)alanyl]azacyclooctane-2(S)-carboxylic acid To a solution of 1-[N-(1-ethoxycarbonyl-3-phenylpropyl)-(S)-alanyl]azacyclooctane-2(S)-carboxylic acid (prepared as described in Example 41) in ethanol, add 0.25 N sodium hydroxide. Afer three hours, concentrate the reaction mixture and absorb it on an XAD-2 resin column and elute with water and then with methanol. Concentrate the methanol eluant to give a residue and absorb this residue on a silica gel column and elute with chloroform: methanol: 14~ ammonium hydroxide l:l:l. Concentrate the desired eluant fraction to obtain the title compound.
Example 43 1-[N-(1-ethoxycarbonyl-3-phenylpropyl)-(S)-alanyl]azacyclo-nonane-~S)-carboxylic acid According to the method of Example 41, starting with ethyl azacyclononane-2-carboxylate, prepare the title com-pound.
Example 44 1-[N-a-(1-ethoxycarbonyl-3-phenylpropyl)-(S)-lysyl]azacyclo-decane-2(S)-carboxylic acid - 55 - ~34~2o s A. According to the method of Example 41A, combine 10.6 g ethyl azacyclodecane-2-carboxylate with 25.4 g N-a-t-butoxycarbonyl-N-E-carbobenzyloxy-L-lysine, N-hydroxy-succinimide ester to produce ethyl 1-[N-a-t-butoxycarbonyl-N-c-carbobenzyloxy-(S)-lysyl]azacyclodecane-2(S)-carboxy-late B. Dissolve the above product in acetonitrile-aqueous NaOH (pH 13), stir for one hour, concentrate, neutralize to pH 8 and extract with ethyl acetate. Dry the ethyl acetate, and add an equal volume of 4N hydrogen chloride in the same solvent. Concentrate, and triturate the residue with ether to give a solid, 1-[N-E-carbobenzyloxy-(S)-lysyl]azacyclo-decane-2(S)-carboxylic acid, hydrochloride.
C. Combine 2.4 g of the above product with 0.8 g sodium acetate in 100 ml ethanol. Add 4.0 g ethyl 2-oxo-4-phenyl-butyrate and 0.63 g NaCNBH3. After four hours, work up as in Example 41D. Combine the desired chromatography frac-tions in 100 ml ethanol with 0.5 g Pd/C and shake under 3 atm. hydrogen for six hours. Filter the catalyst and remove the solvent to obtain the title compound.

- 56 - 13120 fi Example 45 4-[N-(1-ethoxycarbonyl-3-phenylpropyl)-(S)-alanyl]-4-aza-1-thiacyclononane-5(S)-carboxylic acid A. According to the method of Example 41), parts A and B, convert ethyl 4-aza-1-thiacyclononane-5-carboxylate into 4-[N-benzyloxycarbonyl-(S)-alanyl]-4-aza-1-thiacyclo-nonane- 5(S)-carboxylic acid.
B. Dissolve 2.4 g of the above acid in 20 ml of 20~
hydrobromic acid in glacial acetic acid. Stir at room tem-perature one hour and dilute slowly with ether to obtain 4-[(S)-alanyl]-4-aza-1-thiacyclononane-5(S)-carboxylic acid, hydrobromide salt.
C. Dissolve the above salt in 100 ml ethanol and add sodium carbonate (0.30 g) and ethyl 2-oxo-4-phenylbutyrate (l.l g). Add 10 ml of 3 Angstrom molecular sieve pellets and stir twenty hours. Filter and add sodium cyanoboro-hydride (0.60 g). Stir four hours, concentrate, add 10 ml 1N
hydrochloric acid and stir one hour. Place on 200 ml of XAD-2 resin, wash with 2.0 liters of water, and elute with 2.0 liters of methanol. Concentrate the methanol and place on a column of silica gel (0.5 kg). Elute with chloroform:
ethanol:7$ ammonium hydroxide l:l:l to obtain 4-[N-(1-ethoxycarbonyl-3-phenylpropyl-(S)'-alanyl]-4-aza-1-thia-cyclononane-5-(S)-carboxylic acid.

_5~- 134120 Example 46 5-[N-(1(S)-carboxy-5-aminopentyl)-(R, S)-alanyl]-5-aza-1-oxacyclooctane-4(S)-carboxylic acid A. Resolve 5-aza-1-oxacyclooctane-4-carboxylic acid as its d-camphorsulfonate. Dissolve in methanol and treat with thionyl chloride to obtain the methyl ester hydro-chloride. Treat with pyruvic acid, triethylamine and dicyclohexylcarbodiimide in methylene chloride. Isolate methyl 5-pyruvoyl-5-aza-1-oxacyclooctane-4(S)-carboxylate by silica gel chromatography.
B. Combine 2.55 g of the above compound with 1-amino-1-methoxycarbonyl-5-benzyloxycarbonylaminopentane (from 9.8 g of the hydrochloride salt) in 50 ml methanol, stir overnight and add 2.1 g NaCNBH3. Stir overnight, concentra-to and chromatograph on XAD-2 resin to obtain 5-[N-(1(S)-methoxycarbonyl-5-benzyloxycarbonylaminopentyl)-(R,S)-alanyl]-5-aza-1-oxacyclooctane-4(S)-carboxylic acid, methyl ester.
C. Dissolve the above material in 100 ml of methanol with 0.5 g lOo Pd/C and hydrogenate six hours at 3 atm. Filter, add 20 ml 1.ON NaOH, and stir two hours. Add 20 ml 1.ON HC1 and remove the solvent. Chromatograph on XAD-2 resin to obtain the title compound.

_ 134120 6 Example 47 1-[N-(1-carbomethoxy-3-phenylpropyl)-(S)-alanyl]-hexahydro-furo[3.4-b]pyrrole-2(S)-carboxylic acid A. To a solution of ethyl hexahydrofuro[3.4-b]pyrrole-2-carboxylate in ethyl acetate add N-benzyloxycarbonyl-(S)-alanine, N-hydroxysuccinimide ester. Stir the reaction mixture at room temperature for 20 hours and concentrate it in vacuo. Place the residue on a column of silica gel (3000 g, 60-200 mesh) and elute with chloroform: ethyl acetate 10:1 to give 1-[N-benzyloxycarbonyl-(S)-alanyl]-hexahydrofuro[3.4-b]pyrrole-2(R)-carboxylic acid, ethyl ester, and 1-jN-benzyloxycarbonyl-(S)-alanyl]hexahydrofuro-[3.4-b]pyrrole-2(S)-carboxylic acid, ethyl ester.
B. To a solution of 1-jN-benzyloxycarbonyl-(S)-alanyl]-hexahydrofuro[3.4-b]pyrrole-2(S)-carboxylic acid, ethyl ester in methanol, add 2.5 N sodium hydroxide and stir the .
mixture at room temperature for 18 hours. Concentrate the mixture under nitrogen, dilute the residue with ice-water and then make the mixture acidic with concentrated hydro-chloric acid. Extract the aqueous solution with ethyl acetate and dry the organic phase over magnesium sulfate.
Concentrate the organic phase and place it on a column of silica gel. Elute with chloroform:glacial acetic acid 9:1 to give 1-[N-benzyloxycarbonyl-(S)-alanyl]hexahydrofuro-[3.4-b]pyrrole-2(S)-carboxylic acid.

C. Dissolve 1-[N-benzyloxycarbonyl-(S)-alanyl]hexa-hydrofuro[3,4-b]pyrrole-2(S)-carboxylic acid in methanol.
Add 10$ palladium-on-charcoal and hydrogenate the mixture at atmospheric pressure. Filter the mixture and concentrate in vacuo to give 1-[(S)-alanyl]hexahydrofuro[3.4-b]pyrrole-2(S)-carboxylic acid.
D. Dissolve 1-[(S)-alanyl]hexahydrofuro[3.4-b]pyrrole-2(S)-carboxylic acid (prepared in paragraph C of this example) in absolute methanol. Add 2-oxo-4-phenylbutyric lp acid, methyl ester and 3 Angstrom molecular sieve pellets, and stir the resulting mixture at room temperature for eighteen hours. Filter the reaction mixture and treat the filtrate with sodium cyanoborohydride at room temperature for two hours.
Concentrate the mixture under nitrogen and dilute the oil with dilute hydrochloric acid and stir at room temperature for one hour. Absorb the aqueous solution on XAD-2 (Rohm & Hass Co.) resin. Elute the resin with water and then with methanol. Concentrate the methanol solution and place the 2p residue on a column of silica gel and elute with chloroform:
isopropanol: 7a ammonium hydroxide 1:1:1 (organic layer) to give 1-[N-(1-methoxycarbonyl-3-phenylpropyl)-(S)-alanyl]-hexahydrofuro[3.4-b]pyrrole-2(S)-carboxylic acid.

- 60 - 134120 6 ' Example 48 1-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]hexahydrofuro-[3,4-b]pyrrole-2(S)-carboxylic acid To a solution of 1-[N-(1-carbomethoxy-3-phenylpropyl)-(S)-alanyl]hexahydrofuro[3.4-b]pyrrole-2(S)-carboxylic acid (prepared as described in Example 47) in methanol, add 2.5N sodium hydroxide. After three hours, concentrate the reaction mixture and absorb it on a XAD-2 resin column and elute with water and then with methanol. Concentrate the methanol eluant to give a residue and absorb this residue on a silica gel column and elute with chloroform: methanol:
14g ammonium hydroxide 1:1:1. Concentrate the desired eluant fractions to obtain the title compound.
Example 49 1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]hexahydro-furo[3,4-b]pyrrole-2(S)-carboxylic acid React 1-[(S)-alanyl]hexahydrofuro[3.4-b]pyrrole-2-(S)-carboxylic acid (prepared as described in Example 47) and ethyl phenyl-2-oxobutyrate with sodium cyanoborohydride as described in Example 47D (ethanol solvent) to obtain the title compound.

Example 50 1-[N-(1-carboethoxy-3-p-chlorophenylpropyl)-(S)-alanyl]-hexahydrofuro[3.4-b]pyrrole-2(S)-carboxylic acid Treat 1- [ ( S ) -alanyl ] hexahydrofuro [ 3. 4-b] pyrrole-2 ( S ) -carboxylic acid (prepared as described in Example 47) and ethyl 4-(~-chlorophenyl)2-oxobutyrate with sodium cyano-borohydride as described in Example 47D (ethanol solvent) to obtain the title compound.
Example 51 1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]hexahydro-thieno[3,4-b]pyrrole-2(S)-carboxylic acid Use ethyl hexahydrothieno[3,4-b]pyrrole-2-carboxy-late in place of ethyl hexahydrofuro[3,4-b]pyrrole-2-carboxylate in Example 47A. Continue the sequence of re-actions described in Example 47 through Example 47D to obtain the title compound. Example 47C is modified to employ HBr in acetic acid for liberation of the dipeptide.
Example 52 1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]octahydro-pyrano[4,3-b]pyrrole-2(S)-carboxylic acid Use ethyl cis-octahydropyrano[4,3-b]pyrrole-2-carboxy-late in place of ethyl hexahydrofuro[3,4-b]pyrrole-2-carbo-xylate in Example 47A-through 47D to give the title compound.

Example 53 1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]octahydro-thiopyrano[4,3-b]pyrrole-2(S)-carboxylic acid Use ethyl octahydrothiopyrano[4,3-b]pyrrole-2-carboxy-late in place of ethyl hexahydrofuro[3.4-b]pyrrole-2-carboxy late in the procedure described in paragraphs A through D
of Example 47) (modified as in Example 51) to gi:~e the title compound.
Example 54 1-IN-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]octahydro-furo[3,4-b]pyri:dine-2(S)-carboxylic acid React ethyl octahydrofuro[3,4-b]pfTridine-2-carboxy-late with N-benzyloxycarbonyl-(S)-alanine, N-hydroxy-succinimide ester as described in Example 47A-D to isolate the title compound.
Example 55 7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-2-thia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid Treat 2-thia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid ethyl ester in ethyl acetate with N-benzyloxycarbonyl-(S)-alanine, N-hydroxysuccinimide ester as described in Example 47A-D (modified as in Example 51) to isolate the title com-pound.

Example 56 7-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-2-thia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid Hydrolize 0.18 g of 7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-2-thia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid (prepared as described in Example 55) in 600 ml of methanol with l0 ml of 2.5N sodium hydroxide, concentrate the reaction mixture and absorb it on an XAD-2 resin column and elute with water and then with methanol. Concentrate the methanol eluant to give a residue and absorb this re-sidue on a silica gel column (100 g, 60-200 mesh). Elute the column with chloroform: methanol:l4o ammonium hydroxide 1:1:1 and concentrate the desired eluant fractions to ob-taro the title compound.
Example 57 7-[N-(1(S)-carbomethoxy-3-methylthio)-(R, S)-alanyl]-2-thia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid A. Couple 2-thia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid, methyl ester with pyruvic acid using dicyclohexyl-carbodiimide and triethylamine in dioxane to yield, after isolation and hydrolysis of the ester, 7-pyruvoyl-2-thia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid.

- 64 - 13420 g B. Condense 7-pyruvoyl-2-thia-~-azaspiro[4.4]nonane-8(S)-carboxylic acid and (S)-methionine, methyl ester with sodium cyanoborohydride in methanol at pH ~ for three days at room temperature followed by chromatography on a XAD-2 resi:~ column, using methanol as eluant, to obtain the title campoune.
Example 58 7-[N-(1-carboethoxy-3-phenylpropyl)glycyl]-2-thia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid Couple 2-thia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid, ethyl ester with N-benzyloxycarbonylglycine, N-hydroxysuccinimide ester as described in Example 23C-F
to yield the title compound.
Example 59 7-[N-(1-carboxy-3-phenylpropyl)glycyl]-2-thia-7-azaspiro-[4.4]nonane-8(S)-carboxylic acid As described in Example 48, hydrolise 7-[N-(1-carbo-ethoxy-2-phenylpropyl)glycyl]-2-thia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid (prepared as described in Example 58 with sodium hydroxide to give the title compound.
Example 60 1-jN-(1-carboethoxy-3-phenylpropyl-(S)-alanyl]-7-oxa-1-azaspiro[4.4]nonane-2(S)-carboxylic acid - 65 - 1341206 "
Use 7-oxa-1-azaspiro[4.4]nonane-2-carboxylic acid, ethyl ester in place of hexahydrofuroj3.4-b]pyrrole-2-carboxylic acid, ethyl ester in Example 47A through 47D
to obtain the title compound.
Example 61 2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-8-thia-2-azaspiro[4.5]decane-3(S)-carboxylic acid As described in Example 47A through 47D (modified as in Example 51, substitute 8-thia-2-azaspiro[4.5]decane-3-carboxylic acid, ethyl ester for hexahydrofuro[3,4-b]-pyrrole-2-carboxylic acid, ethyl ester to obtain the title compound.
Example 62 7-[N-(1-carboethoxy-2-phenylpropyl)-(S)-alanyl]-2-oxa-7-azaspiro[4.5]decane-8(S)-carboxylic acid Combine ethyl 2-oxa-7-azaspiro[4.5]decane-8-carboxy-late and N-benzyloxycarbonyl-(S)-alanine, N-hydroxysuccir~-i~n.ide ester by the procedure described in Example 47A-D
to obtain the title compound.
Example 63 N-(1(R)-ethoxycarbonyl-2-benzylthioethyl)-(R, S)-alanyl-(S)-proline hydrochloride.

Mix 8.28 g of S-benzyl-L-cysteine ethyl ester hydro-chloride with NaHC03 solution until basic. Extract with dichloromethane, dry with MgS04, and concentrate to dry-ness at room temperature. Dissolve the residue in 80 ml of tetrahydrofuran containing 2.1 g of pyruvoyl-L-proline and 4 g of 5 Angstrom molecular sieves. Stir for 2 days and then add, dropwise over 4 hours, a solution of sodium cyanoborohydride in 20 ml of ethanol. Stir for 18 hours, filter, and concentrate the filtrate to dryness. Partition :10 the residue between water and dichloromethane. Absorb the aqueous phase on a sulfonic acid on exchange resin and elute with 4o pyridine in water. Concentrate to dryness.
Dissolve the residue in a mixture of 5 ml of methanol and 1500 ml ether. Acidify this solution with 3.5M HC1 in ether :15 and filter the resulting precipitate to obtain 2.5 g of the title compound having a melting point of 90-100°C and [a]D26 - _73.4° (lo, H20).
Example 64 N-(1(S)-ethoxycarbonyl-2-benzyloxyethyl)-(R, S)-alanyl-(S)-2p proline rydrochlcride.
Following the procedure of Example 63, react 5 g of O-benzyl-L-serine ethyl ester hydrochloride with 1.26 g of pyruvoyl-L-proline to yield 1.6 g of the title compound having a melting point of 90-100° and [a~D26 _ -71.3°
25 (1$. H20).

Example 65 1-[N-(1(S)-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octa-hydroindole-2(S)-carboxylic acid Following the procedure of Example 1, but modifying step E to use ethanol as reaction solvent, prepare 1-[N-(1(R,S)-carboethoxy-3-phenylpropyl)-(S)-alanyl-octahydro-indole-2(S)-carboxylic acid. Chromatograph this material on an RP-8 reversed-phase column using acetonitrile .
0.2N NH40Ac 40:60 (pH 8.6) as eluent to obtain the title compound as a solid [aJD26- -45.3° (ethanol).
Example 66 1-~N-[1(S)-carboethoxy-3-phenylpropylJ-(S)-alanyl}-3a(S), 7a(S)-octahydroindole-2(S)-carboxylic acid A. To a 100 ml three-neck flask, equipped with a ther-mometer, dropping funnel, magnetic stirrer and ice bath, 23 ml (0.21 mole) of benzyl alcohol was added and cooled to O°C under N2. SOC12 (5.95 g, 3.7 ml, 0.05 mole) was added dropwise over 15 min, maintaining the temperature at ca. 0°C. Cis,syn-perhydroindole-2(S)-carboxylic acid (ca.
0.21 mole) was added and the mixture was stirred at ca. O°C
for 1 hour and then for 24 hours at room temperature. The resulting mixture was poured into 500 ml of ether, stirred under N2 for 1 hour and then allowed to stand under N2 until it was no longer cloudy. The mixture was decanted and the oily precipitate was washed with 25 ml of ether, then slurried in 200 ml of ether followed by addition of 1N
NaOH to pH 8-9. The mixture was stirred for 5 minutes, and the organic layer was then washed with brine, dried over MgS04, filtered and evaporated in vacuo at room temperature to give 2-(S)-benzyloxycarbonyl-cis,s~n-octahydroindole as a colorless oil (t)c (ether) one spot, RfN0.31.
B. To a 5 1 flask equipped with a magnetic stirrer, dropping funnel and N2 inlet tube, was added a solution of 190 g (0.92 mole) of ethyl 2-oxo-4-phenyl butanoate, and 1.0 258 g (0.734 mole) of S-alanine benzylester p-toluenesulro-nate in 1.4 1 of EtOH. This yellow solution was stirred for 2 hours under N2. A solution of 17.7 g (0.282 mole) of IJa~H3CN in 550 ml of EtpH was then added, with stirring, over 90 minutes. The solution was stirred overnight and concen-trated to dryness in vacuo at room temperature. The residue was partitioned between 500 ml of H20 and 2 1 of ehter and -the ether layer was dried over MgS04 and filtered. To this solution, 1.3M ethereal fiCl was added to pH 4. The ether and excess HC1 were then removed in vacuo at room temperature.
2~~ The residue was slurried in 250 ml of ether and diluted with 750 ml of hexane. The supernatent was decanted from the re-sulting precipitate. The precipitate was washed with two 300 ml portions of ether as above. The residue was then tritura-ted with 300 ml of ether and filtered under N2 to give a white solid. This was slurried in ether and made basic with saturated aqueous NaHC03. The organic layer was dried over MgS04, filtered and concentrated in vacuo at room tempera-ture to give a yellow oil. This oil was dissolved in 510 ml of EtOAc, to which was added a hot solution of 40.5 g of malefic acid in 895 ml of EtOAc. Afer cooling to room tempe-rature the resulting precipitate was filtered and recrystal-lized from EtOAc to give hemimaleate as a white solid, mp 127-128°C, [a)D6 O° (c=lg H20) [tlc (cyclohexane: EtOAc-85:15) shows one spot (Rf 0.30) after neutralization].
7.0 g (.015 mole) of the so obtained product was slurried in EtOAc and made basic with saturated aqueous NaHC03. The or-ganic layer was washed with brine, dried over MgS04, filtered and concentrated in vacuo at room temperature to give the product as a colorless oil. This was dissolved in 100 ml of EtOH containing 0.7 g of 10g Pd/C. The mixture was hydroge-nated in a Parr shaker at 60 psi (rt) for 2 hours. After fil-tration, the solvent was removed in vacuo at room temperature to afford 4.0 g (820) of N-(1-(S)-ethoxycarbonyl-3-phenylpro-pyl)-(S)-alanine as a white solid, mp 147-148°C, [a]D6 +
24.8° (c= 1~ MeOH) [Rf O.1(EtOAc:MeOH:HOAc-100:1:1)J.
C. To a 50 ml three-neck flask equipped with a dropping funnel, thermometers magnetic stirrer and an ice bath, a so-lution of 0.23 g of 2-(S)-benzyloxycarbonyl-cis,syn-octa-hydroindole and 0.25 g (0.0009 mole) of N-(1-(S)-ethoxy-carbonyl-3-phenylpropyl)-(S)-alanine in 5.0 ml of DMF

_ 70 _ 134120 8 was added and cooled under N2 to O°C. With sirring, 0.14 g, (0.00135 mole) of N-methylmorpholine was added, followed by dropwise addition (5 min) of a solution of 0.25 g (0.0009 mole) of diphenylphosphorylazide in 5 ml of DMF, (temperature of mixture maintained at O-10°C). The solution was stirred at this temperature for 1 hour and then at room temperature overnight. Saturated aqueous NaHC03 was added to the ligth yellow solution to pH 8. It was then extracted with ether, dried over MgS04, filtered and evaporated in'vacuo at room 1.0 temperature to give 0.43 g of crude product as a yellow oil.
This was preadsorbed on 1 g of coarse (60-200 mesh) silica gel and then gravity filtered through 40 g of coarse silica gel (60-200 mesh) with ca. 300 ml of ether. 1-{N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-(S)-alanyll-cis,s~n-octahydro-indole-2-(S)-carboxylic acid benzyl ester was obtained as a colorless oil.
D. 0.20 g (0.00038 mole) of the so obtained product was dissolved in 50 ml of EtOH containing 0.04 g of 10~ ~d/C.
The mixture was hydrogenated in a Parr shaker at 60 psi (rt) for 2 hours. The mixture was filtered and the filtrate was evaporated in vacuo at room temperature to yield the title compound as a colorless oil.
Example 67 1-~N-[1(S)-carboethoxy-3-phenylpropyl]-(S)-alanyl~-3a(S), 7a(S)-octahydroindole-2(S)-carboxylic acid N-(1-(S)-ethoxycarbonyl-3-phenylpropyl)-(S)-alanine (400 mg, 0.0014 mole) (obtainable according to example 66 step B) was dissolved in 40 ml of dry CH3CN containing 0.417 g (0.0014 mole) of N, N-disuccinimidyl carbonate. Dry pyridine (0.10 ml, 0.0014 mole) was added and the solution was stir-red at room temperature under N2 overnight. Cis,s~n-per-hydroindole-2(S)-carboxylic acid (0.0014 mole) and 0.25 ml Et3N were then added and the mixture was stirred overnight.
The solvent was evaporated in vacuo at room temperature to give a yellow gum. This was chromatographed on 100 g silica gel (tlc grade - EtOAc:MeOH:HOAc-100:1:1) to afford the title compound as its acetate salt (gum).

1341~0 6 ' The following compounds exemplify the compounds of formu-la I, which can be prepared according to the described processes:
1-[N-(1-Carbomethoxy-3-phenylpropyl)-(S)-alanyl]octahydro-indole-2(S)-carboxylic acid;
1-[N-(1-Carboxy-3-phenylpropyl)-(S)-alanyl]octahydroindole-2(S)-caboxylic acid;
1-[N-(1-Carboethoxy-3-p-chlorophenylpropyl)-(S)-alanyl]
octahydroindole-2(S)-carboxylic acid;
1-[N-(1-Carboxy-3-p-chlorophenylpropyl)-(S)-alanyl]octa-hydroindole-2(S)-carboxylic acid;
1-[N-(1-Carboxy-2-phenylethyl)-(S)-alanyl]octahydroindole-2(S)-carboxylic acid;
1-[N-(1-Aminocarbonyl-3-phenylpropyl)-(S)-alanyl]octahydro-15 indole-2(S)-carboxylic acid;
1-~N-[1-Carboxy-3-(3-indolyl)propyl]-(S)-alanylyoctahydro-indole-2(S)-carboxylic acid;
1-~N-[1-Carboethoxy-2-(3-indolyl)ethyl]-(S)-alanyl}octahydro-indole-2(S)-carboxylic acid;
2C 1-[N~(1-Carboxy-2-phenoxyethyl)-(S)-alanyl]octahydroindole-2(S)-carboxylic acid;
1-[N-(1-Carboethoxy-2-phenoxyethyl)-(S)-alanyl]octahydroin-dole-2(S)-carboxylic acid;
1-[N-(1-Carboxy-2-phenylthioethyl)-(S)-alanyl]octahydro-2-'' indole-2(S)-carboxylic acid;

- ~3 - 134120 6 1-(N-(1-Carboxyethyl)-(S)-alanyl]octahydroindole-2(S)-carboxylic acid;
1-[N-(1-Carboxy-2-cyclohexylethyl)-(S)-alanyl]octahydro-indole-2(S)-carboxylic acid;
1-[N-(1-Carboxy-5-methylhexyl)-(S)-alanyl]octahydroindole-2(S)-carboxylic acid;
1-(N-(1,3-Dicarboxypropyl)-(S)-alanyl]octahydroindole-2(S)-carboxylic acid;
1-[N-(1-Carboethoxy-3-phenylpropyl-(S)-alanyl]decahydro-quinoline-2(S)-carboxylic acid;
1-[N-(1-Carboxy-3-phenylpropyl)-(S)-alanyl]decahydroquino-line-2(S)-carboxylic acid;
2-[N-(1-Carboethoxy-3-phenylpropyl)-(S)-alanyl]octahydro-isoindole-1(S)-carboxylic acid;
2-[N-(1-Carboxy-3-phenylpropyl)-(S)-alanyl]octahydroisoin-dole- 1(S)-carboxylic acid;
1-[N-(1-Carboethoxy-3-phenylpropyl)-(S)-alanyl]octahydro-cyclopenta[b]pyrrole-2(S)-carboxylic acid;
1-[N-(1-Carboxy-3-phenylpropyl)-(S)-alanyl]octahydrocyclo-penta[b]pyrrole-2(S)-carboxylic acid;
5-[N-(1-Carboethoxy-3-phenylpropyl)-(S)-alanyl]-2,2-dime-thyloctahydro-1,3-dioxolo[4,5-c]pyrrole-4(S)-carboxylic acid;
7-[N-(1-Carboxy-3-phenylpropyl)-(S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
7-[N-(1-Carboxy-3-phenylpropyl)-(S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;

-~4- 13412Q6 7-[N-(1-Carbomethoxy-3-methylthiopropyl)-(R,S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
~-[N-(1-Carboxy-3-methylthiopropyl)-(R, S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
~-;N-(1-Carbomethoxy-2-(3-indolyl)ethyl]-(R, S)-alanyl'}-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
7-tN-[1-Carboxy-2-(3-indolyl)ethyl]-(R, S)-alanyl}-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
7-~N-[1-Carbomethoxy-2-(1H-imidazol-4-yl)ethyl]-(R,S)-alanyl} -1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
7-~N-[1-Carboxy-2-(1H-imidazol-4-yl)ethyl]-(R,S)-alanyl}-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
7-[N-(1-Carboethoxy-3-phenylpropyl)glycyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
7-[N-(1-Carboxy-3-phenylpropyl)glycyl]-1,4-dithia-7-azaspiro-[4.4]nonane-8(S)-carboxylic acid;
7-[N-(1-Carboethox~~-3-Phenylpropyl)-(S)-alanyl]-1,4-dithia-7-azaspiro[4.5]decane-8(S)-carboxylic acid;
~-[N-(1-Carboxy-3-phenylpropyl)-(S)-alanyl]-1,4-dithia-7-azaspiro[4.5]decane-8(S)-carboxylic acid;
1-[N-(1-Carboethoxy-3-phenylpropyl-(S)-alanyl]-1-azaspiro-[4.4]-nonane-2(S)-carboxylic acid;
2-[N-(1-Carboethoxy-3-phenylpropyl)-(S)-alanyl]-2-azaspiro-[4.4]-nonane-3(S)-carboxylic acid;
1-(N-(1-Carboethoxy-3-phenylpropyl)-(S)-alanyl]-4(R,S)-[2-(1,3-dithianyl)]-(S)-proline;

- ~5 - 134120 6 N-[N-(1-Carbomethoxy-3-phenylpropyl)-(S)-alanyl]-N-cyclo-hexyl-(S)-alanine;
N-~{N-[(1-Carbomethoxy-3-phenylpropyl)-(S)-alanyl]}-N-(2,2-diethoxy)ethyl-(S)-alanine;
N-[N-(1-Carboethoxy-3-phenylpropyl)-(S)-alanyl]-N-[2-(1,3-dithianyl)methyl]-(S)-alanine;
1-[N-(1-Ethoxycarbonyl-3-phenylpropyl)- (S)-alanyl) azacyclo-octane-2(S)-carboxylic acid;
1-jN-(1-Carboxy-3-phenylporpyl)-(S)-alanyl]azacyclooctane-2(S)-carboxylic acid;
1-[N-(Ethoxycarbonyl-3-phenylpropyl)-(S)-alanyl]azacyclo-nonane-2(S)-carboxylic acid;
1-[N-a-(1-Ethoxycarbonyl-3-phenylpropyl)-(S)-lysyl]aza-cyclodecane-2(S)-carboxylic acid;
:15 4-[N-(1-Ethoxycarbonyl-3-phenylpropyl)-(S)-alanyl]-4-aza-1-thiacyclononane-5(S)-carboxylic acid;
5-[N-(1(S)-carboxy-5-aminopentyl)-(R,S)-alanyl]-5-aza-1-oxacyclooctane-4(S)-carboxylic acid;
1-[N-(1-Cark~zn~hoxy-3-phenylpropyl)-(S)-alanyl]-hexahydro-furo[3,4-b]pyrrole-2(S)-carboxylic acid;
1-[N-(1-Carboxy-3-phenylpropyl)-(S)-alanyl]hexyhydrofuro-[3,4-b]pyrrole-2(S)-carboxylic acid;
' 1-[N-(1-Carboethoxy-3-phenylpropyl)-(S)-alanyl]-hexahydro-furo[3,4-b]pyrrole-2(S)-carboxylic acid;
1-[N-(1-Carboethoxy-3-p-chlorophenylpropyl)-(S)-alanyl]-hexahydrofuroj3,4-b]pyrrole-2(S)-carboxylic acid;

134120 6 ' 1-[N-(1-Carboethoxy-3-phenylpropyl)-(S)-alanyl]-hexahydro-thieno[3,4-b]pyrrole-2(S)-carboxylic acid;
1-IN-(1-Carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-pyrano[4,3-b]pyrrole-2(S)-carboxylic acid;
1-[N-(1-Carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-thiopyrano[4,3-b]pyrrole-2(S)-carboxylic acid;
1-jN-(1-Carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-furo(3,4-b]pyridine-2(S)-carboxylic acid;
7-[N-(1-Carboethoxy-3-phenylpropyl)-(S)-alanyl]-2-thia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
7-[N-(1-Carboxy-3-phenylpropyl)-(S)-alanyl]-2-thia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
7-[N-(1(S)-Carbomethoxy-3-methylthio)-(R, S)-alanyl]-2-thia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
7-[N-(1-Carboethoxy-3-phenylpropyl)glycyl]-2-thia-7-azaspiro-[4.4]nonane-8(S)-carboxylic acid;
7-[N-(1-Carboxy-3-phenylp ropyl)glycyl]-2-thia-7-azaspiro-[4.4]nonane-8(S)-carboxylic acid;
1-[N-(1-Carboethoxy-3-phenylpropyl-(S)-alanyl]-7-oxa-1-'ZO azaspiro-[4.4]nonane-2(S)-carboxylic acid;
2-[N-(1-Carboethoxy-3-phenylpropyl-(S)-alanyl]-8-thia-2-azaspiro[4.5]decane-3(S)-carboxylic acid;
7-[N-(1-Carboethoxy-3-phenylpropyl)-(S)-alanyl]-2-oxa-7-azaspiro[4.5]decane-8(S)-carboxylic acid;
N-(1(R)-Ethoxycarbonyl-2-benzylthioethyl)-(R, S)-alanyl-(S)-proline hydrochloride;

- ~~ _ 134 20 6 N-(1(S)-ethoxycarbonyl-2-benzyloxyethyl)-~,S)-alanyl-(S)-proline hydrochloride;
1-[N-(1(S)-carboethoxy-3-phenylpropyl)-(S)-alanyl- octa-hydroindole-2(S)-carboxylic acid;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-indole-2(S)-carboxylic acid;
1-[N-(1-carboethoxy-2-phenylethyl)-(S)-alanyl]-octahydro-indole-2(S)-carboxylic acid;
1-[N-(1-carboxy-2-phenylethyl)-(S)-alanyl]-octahydroindole-1.0 2 (S ) -carboxylic acid;
1-[N-(1-carboethoxy-2-phenylthioethyl)-(S)-alanyl]-octahydro-indole-2(S)-carboxylic acid;
1-[N-(1-carbomethoxy-3-phenylpropyl)-(S)-alanyl]-decahydro-cyclohepta[b]pyrrole-2(S)-carboxylic acid;
7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1-thia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
1-[N-(1-carbomethoxy-3-phenylpropyl)-(S)-lysyl]-octahydro-indole-2(S)-carboxylic acid;
1-[N-(1-carboethoxy-2-benyloxyethyl)-(S)-alanyl]-octahydro-indole-2(S)-carboxylic acid;
N-(1-carboethoxy-2-benzylthioethyl)-(S)-alanyl]-octahydro-indole-2(S)-carboxylic acid;
1-[N-(1-carboethoxyethyl)-(S)-alanyl]-octahydroindole-2(S)-carboxylic acid;
1-[N-(1-carboethoxy-2-cyclohexylethyl)-(S)-alanyl]-octahydro-indole-2(S)-carboxylic acid;

- ~s _ 1-[N-(1-carboethoxy-5-methylhexyl)-(S)-alanyl]-octahydro-indole-2(S)-carboxylic acid;
- 1-[N-(1-carbomethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-cyclopenta[b]pyrrole-2(S)-carboxylic acid;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-cyclopenta[c]pyrrole-2(S)-carboxylic acid;
1-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-octahydrocyclo-penta[c]pyrrole-2(S)-carboxylic acid;
1-(N-(1-carbomethoxy-3-phenylpropyl)-(S)-alanyl]-decahydro-quinoline-2(S)-carboxylic acid;
'~ 1-[N-(1-carboxy-3-phenylpropyl)glycyl]-decahydroquinoline-2(S)-carboxylic acid;
1-[N-(1-carboethoxy-3-p-chlorophenylpropyl)-(S)-alanyl]-decahydroquinoline-2(S)-carboxylic acid;
'~ ~-5 1-[N-(1-carboxy-2-phenylethyl)-(S)-alanyl]-octahydroiso-indole-1(S)-carboxylic acid;
' 4-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-furo[3,2=b]pyrrole-5(S)-carboxylic acid;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-pyrano[3,2-b]pyrrole-2(S)-carboxylic acid;
4-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-thieno[3,2-b]pyrrole-5(S)-carboxylic acid;
5-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-furo[2,3-c]pyrrole-4(S)-carboxylic acid;
5-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-thieno[2,3-c]pyrrole-4(S)-carboxylic acid;

- 79 _ ~3~z2o s 4-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-furo[3,2-b]pyridine-5(S)-carboxylic acid;
5-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-decahydro-pyrano[3,2-b] pyridine-6(S)-carboxylic acid;
4-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-thieno[3,2-b]pyridine-5(S)-carboxylic acid;
5-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-decahydro-thiopyrano[3,2-b]-pyridine-6(S)-carboxylic acid;
6-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-furo[2,3-c]pyridine-5(S)-carboxylic acid;
7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-decahydro-pyrano[2,3-c]pyridine-6(S)-carboxylic acid;
6-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl-octahydro-thieno[2,3-c]pyridine-5(S)-carboxylic acid;
7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-decahydro-thiopyrano[2,3-c]pyridine-6(S)-carboxylic acid;
5-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-2,2-dimethyl-octahydro-1,3-dioxolo[4,5-c]pyrrole-4(S)-carboxylic acid;
6-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-octahydro-1,4-dioxino[2,3-c]pyrrole-5(S)-carboxylic acid;
5-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-octahydro-1,3-dithiolo[4,5-c]pyrrole-4(S)-carboxylic acid;
6-[N-(1-carboxy-3-phenylpropyl-(S)-alanyl]-octahydro-1,4-dithiino[2,3-c]pyrrole-5(S)-carboxylic acid;
5-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-2,2-dimethyl-octahydro-1,3-dioxolo[4,5-c]pyridine-6(S)-carboxylic acid;

- 6-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-decahydro-1,4-dioxino[4,5-c]pyridine-7(S)-carboxylic acid;
5-jN-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-octahydro-1,3-dithiolo[4,5-c]pyridine-6(S)-carboxylic acid;
6-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-decahydro-1,4-dithiino[2,3-c]pyridine-7(S)-carboxylic acid;
5-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-octahydro-1,3-dioxolo[4,5-c]pyridine-4(S)-carboxylic acid;
6-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-decahydro-1,4-dioxino[2,3-c]pyridine-5(S)-carboxylic acid;
5-jN-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-octahydro-1,3-dithiolo[4,5-c]pyridine-4(S)-carboxylic acid;
6-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-decahydro-1,4-dithiino[2,3-c]pyridine-5(S)-carboxylic acid;
7-[N-(1-carboethoxy-3-p-chlorophenylpropyl)-(S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
7-[N-(1-carboxy-3-p-chlorophenylpropyl)-(S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
7-[N-(1-carboxy-2-phenoxyethyl)-(S)-alanyl]-1,4-dithia-7-azaspiroj4.4]nonane-8(S)-carboxylic acid;
7-[N-(1-carbomethoxy-3-methylthiopropyl)-(R,S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
7-[N-(1-carboxy-3-methylthiopropyl)-(R, S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
7-;N-[1-carboethoxy-2-(3-indolyl)ethyl]-(R, S)-alanyl~-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;

7-~N-[1-carboxy-2-(3-indolyl)ethyl]-(R, S)-alanyl~-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
7-tN-[1-carboethoxy-2-(1H-imidazol-4-yl)ethyl]-(R, S)-alanyl~-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
7-[N-(1-carbomethoxy-3-phenylpropyl)glycyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
- 7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1,4-dioxa-7-azaspiro[4.4]nonane-8(S)carboxylic acid;
2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-6,10-dioxa-2-azaspiro[4.5]decane-3(S)-carboxylic acid;
2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-6,10-dithia-2-azaspiro[4.5]decane-3(S)-carboxylic acid;
7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1,4-dioxa-7-azaspiro[4.4]nonane-6(S)-carboxylic acid;
2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-6,10-dioxa-2-azaspiro[4.5]decane-1(S)-carboxylic acid;
7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-6(S)-carboxylic acid;
2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-6,10-dithia-2Q 2-azaspiro[4.5]decane-1(S)-carboxylic acid;
7-[N-(1-carboethoxy-3-phenylpropyl)-(S)alanyl]-1,4-dioxa-7-azaspiro[4.5]decane-8(S)-carboxylic acid;
7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1,4-dithia-7-azaspiro[4.5]decane-8(S)-carboxylic acid;
8-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1,5-dithia-8-azaspiro[5.5]undecane-9(S)-carboxylic acid;

8-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1,4-dioxa-8-azaspiro[4.5]decane-7(S)-carboxylic acid;
9-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1,5-dioxa-9-azaspiro[5.5]undecane-8(S)-carboxylic acid;
.5 8-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1,4-dithia-8-azaspiro[4.5]decane-7(S)-carboxylic acid;
9-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1,5-dithia-9-azaspiro[5.5]undecane-8(S)-carboxylic acid;
1-[1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-4,4-dimethoxy-1~ (S)-proline;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)--alanyl-5,5-dimethoxy-(S)-pipecolic acid;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-3,3-dimethoxy-(S)-proline;
15 1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-4,4-dimetho-xy-(S)-pipecolic acid;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-4,4-di(ethyl-thio)-(S)-proline;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-3,3-di(ethyl-20 thio-(S)-proline;
1-[N-(1-carboethoxy-3-phenylpropyl-(S)-alanyl]-5,5-di(ethyl-thio)-(S)-pipecolic acid;
1-jN-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-4,4-di(ethyl-thio)-(S)-pipecolic acid;
2.5 1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1-azaspiro-[4.5]decane-2(S)-carboxylic acid;

-$3- 1341206 2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-2-azaspiro-[4.5]decane-3(S)-carboxylic acid;
2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-2-azaspiro-[4.5]decane-7(S)-carboxylic acid;
2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1-azaspiro-[5.5]undecane-2(S)-carboxylic acid;
2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-7-azaspiro-[4.5]decane-8(S)-carboxylic acid; , 2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-2-azaspiro-lU [5.5]undecane-3(S)-carboxylic acid;
8-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-8-azaspiro-[4.5]decane-7(S)-carboxylic acid;
3-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-3-azaspiro-[5.5]undecane-2(S)-carboxylic acid;
7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1-oxa-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1-oxa-7-azaspiro[4.4]nonane-6(S)-carboxylic acid;
7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1-oxa-7-azaspiro[4.5]decane-8(S)-carboxylic acid;
8-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1-oxa-8-azaspiro[5.5]undecane-9(S)-carboxylic acid;
8-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1-oxa-8-azaspiro[4.5]decane-7(S)-carboxylic acid;
9-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1-oxa-9-azaspiro[5.5]undecane-8(S)-carboxylic acid;

1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-4(R,S)-(1,3-dioxolan-2-yl)-(S)-proline;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-4(R,S)-(1,3-dioxan-2-yl)-(S)-proline;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-4(R,S)-(1,3-dithiolan-2-y1)-(S)-proline;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-4(R,S)-dimethoxymethyl-(S)-proline;
' 1- [N- ( 1-carboethoxy-3-phenylpropyl ) - ( S ) -alanyl ] -4 ( R, S ) -di-(ethylthio)methyl-(S)-proline;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-4(R,S)-(2-tetrahydrofuryl)-(S)-proline;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-4(R,S)-(2- tetrahydropyranyl)-(S)-proline;
1-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-4(R,S)-(1,3-dioxolan-2-yl)-(S)-proline;
1-[N-(1- carboxy-3-phenylpropyl)-glycyl]-4(R,S)-(1,3-dioxa-lan-2-yl)-(S)-proline;
1-[N- (1-carboxy-3-phenylpropyl)-(S)-alanyl]-4(R,S)-(1,3-2c7 dithiolan-2-yl)-(S)-proline;
1-[N-(1-carboxy-3-phenylpropyl)-glycyl]-4(R,S)-(1,3-dithiolan-2-yl)-(S)-proline;
1-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-4(R,S)-dimethoxy-methyl-(S)-proline;
1-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-4(R,S)-di(ethyl-thio)methyl-(S)-proline;

- 85 - 134 2o s , 1-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-4(R,S)-(2-tetrahydrofuryl)-(S)-proline;
1-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-4(R,S)-(2-tetrahydropyranyl)-(S)-proline;
1-[N-(1-carboxy-3-phenylpropyl)-glycyl]-4(R,S)-(2-tetrahydropyranyl)-(S)-proline;
N-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-N-(2,2-diethoxy)ethyl-(S)-alanine;
N-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-N-(1,3-dioxolan-2-yl)methyl-(S)alanine;
N-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-N-(1,3-dioxan-2-yl)methyl-(S)-alanine;
N-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-N-(1,3-dithiolan-2-yl)methyl-(S)-alanine;
N-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-N-(1,3-dithian-2-yl)methyl-(S)-alanine;
N-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-N-(2-tetrahydrofuryl)methyl-(S)-alanine;
N-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-N-(2-2U tetrahydropyranyl)methyl-(S)-alanine;
N- (N- (1-carboethoxy-3-phenylpropyl) - (S) -alanyl] -N- (2-tetrahydrothienyl)methyl-(S)-alanine;
N-[N-(1-carboethoxy-3-phenylpronyl)-(S)-alanyl]-N-cyclo-hexyl-(S)-alanine;
N-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-N-cyclo-pentyl-(S)-alanine;

- 86 - 13~12o s .
N-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-3-(2-methyl-1,3-dioxolan-2-yl)-(S)-alanine;
N-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-3(2-methyl-1,3-dithiolan-2-yl)-(S)-alanine;
N-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-3-(2-methyl-1,3-dioxan-2-yl)-(S)-alanine;
N-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-3-(2-methyl-1,3-dithian-2-yl)-(S)-alanine;
N-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-3-(2-methyl-2-tetrahydrofuryl)-(S)-alanine;
N-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-3-(2-methyl-2-tetrahydropyranyl)-(S)-alanine;
N-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-3-(2-methyl-2-tetrahydrothienyl)-(S)-alanine;
.L5 N- [N- (1-carboethoxy-3-phenylpropyl) - (S) -alanyl] -3- (2-methyl-2-tetrahydrothiopyranyl)-(S)-alanine;
1-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-azacyclononane-2(S)-carboxylic acid;
1-[N-(1-ethoxycarbonyl-3-phenylpropyl)-(S)-alanyl]-azacyclo-decane-2(S)-carboxylic acid;
1-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-azacyclodecane-2(S)-carboxylic acid;
1-[N-a-(1-methoxycarbonyl-3-phenylpropyl)-(S)-lysyl]-azacyclooctane-2(S)-carboxylic acid;
1-[N-a-(1-carboxy-3-phenylpropyl)-(S)-lysyl]-azacyclononane-2(S)-carboxylic acid;

- s~ - 134120 6 1-[N-(1(S)-carboxy-5-aminopentyl)alanyl]-azacyclononane-2(S)-carboxylic acid;
4-[N-(1-ethoxycarbonyl-3-phenylpropyl)-(S)-alanyl]-4-aza-1-oxacyclooctane-5(S)-carboxylic acid;
4-[N-(1-ethoxycarbonyl-3-phenylpropyl)-(S)-alanyl]-4-aza-1-thiacyclooctane-3(S)-carboxylic acid;
5-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-5-aza-1-oxacyclononane-6(S)-carboxylic acid;
5-[N-(1-ethoxycarbonyl-3-phenylpropyl)-(S)-alanyl]-5-aza-1.0 1-oxacyclononane-4(S)-carboxylic acid;
4-[N-ethoxycarbonyl-3-phenylpropyl)-(S)-alanyl]-4-aza-1-thiacyclononane-3(S)-carboxylic acid;
4-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-4-aza-1-oxacyclodecane-5(S)-carboxylic acid;
5-[N-(1-ethoxycarbonyl-3-phenylpropyl)-(S)-alanyl]-5-aza-1-oxacyclodecane-6(S)-carboxylic acid;
6-[N-(1-methoxycarbonyl-3-phenylpropyl)-(S)-alanyl]-6-aza-1-thiacyclodecane-5(S)-carboxylic acid;
5-[N-(1-ethoxycarbonyl-3-phenylpropyl)-(S)-alanyl]-5-aza-1-oxacyclodecane-4(S)-carboxylic acid;
4-[N-(1-ethoxycarbonyl-3-phenylpropyl)-(S)-alanyl]-4-aza-1-oxacyclodecane-3(S)-carboxylic acid;
1-[N-(1-carbomethoxy-3-phenylpropyl)-(S)-alanyl] hexahydro-furo[3,4-b]pyrrole-2(S)-carboxylic acid;
1-[N-(1-carboethoxy-2-phenylethyl)-(S)-alanyl]hexahydrofuro-(3,4-b]-pyrrole-2(S)-carboxylic acid;

- 88 - 13 4'I 2 0 6 1-[N-(1-carboxy-2-phenylethyl)-(S)-alanyl]hexahydrofuro-[3,4-b] pyrrole-2(S)-carboxylic acid;
5-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]hexahydro-furo[3,4-c]pyrrole-4(S)-carboxylic acid;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]hexahydro-thieno[3,4-b]pyrrole-2(S)-carboxylic acid;
5-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]hexahydro-thieno[3,4-c]pyrrole-4(S)-carboxylic acid;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-pyrano[3,4-b]pyrrole-2(S)-carboxylic acid;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-pyrano[3,4-c]pyrrole-2(S)-carboxylic acid;
2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-pyrano[3,4-c]pyrrole-3(S)-carboxylic acid;
2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-pyrano[3,4-c]pyrrole-1(S)-carboxylic acid;
1-[N-(1-carboethoxy-3-phenylpropyl-(S)-alanyl~-octahydro-thiopyrano[4,3-b]pyrrole-2(S)-carboxylic acid;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-thiopyrano[3,4-b]pyrrole-2(S)-carboxylic acid;
3-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-thiopyrano[3,4-c]pyrrole-1(S)-carboxylic acid;
2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-thiopyrano[3,4-c]pyrrole-3(S)-carboxylic acid;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-furo[3,4-b]pyridine-2(S)-carboxylic acid;

- 8~ - 13 412 0 6 .
5-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-furo[3,4-c]pyridine-6(S)-carboxylic acid;
5-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-furo[3,4-c]pyridine-4(S)-carboxylic acid;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-thieno[3,4-b]pyridine-2(S)-carboxylic acid;
5-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-thieno[3,4-c]pyridine-6(S)-carboxylic acid;
5-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-l~ thieno[3,4-c]pyridine-4(S)-carboxylic acid;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-pyrano[3,4-b]pyridine-2(S)-carboxylic acid;
- 1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-pyrano[4,3-b]ny~idine-2(S')-carboxylic acid;
7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-pyrano[3,4-c]pyridine-6(S)-carboxylic acid;
6-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-pyrano[4,3-c]pyridine-7(S)-carboxylic acid;
6-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-2~ pyrano[4,3-c]pyridine-5(S)-carboxylic acid;
7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-pyrano[3,4-c]pyridine-8(S)-carboxylic acid;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-thiopyrano[3,4-b]pyridine-2(S)-carboxylic acid;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-octahydro-thiopyrano[4,3-b]pyridine-2(S)-carboxylic acid;

134120 6 ' 7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alynal]octahydro-thiopyrano[3,4-c]pyridine-6(S)-carboxylic acid;
6-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]octahydro-thiopyrano[4,3-c]pyridine-7(S)-carboxylic acid;
6-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]octahydro-thiopyranoj4,3-c]pyridine-5(S)-carboxylic acid;
7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]octahydro-thiopyrano[3,4-c]pyridine-8(S)-carboxylic acid;
5-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]octahydrofuro-[3,4-c]pyridine-y S)$carboxylic acid;
1-[N-(1-ca~boxy-3-phenylpropyl)-(S)-alanyl]octahydrothieno-[3,4-b]pyridine-2(S)-carboxylic acid;
5-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]octahydrothieno-(3,4-c]pyridine-4(S)-carboxylic acid;
1_'~ 1-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]octahydropyrano-[3,4-b]pyridine-2(S)-carboxylic acid;
7-jN-(1-carboxy-3-phenylpropyl)-(S)-alanyl]octahydropyrano-[3,4-c]pyridine-6(S)-carboxylic acid;
7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-2-oxa-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
1-[N-(1-carbomethoxy-3-pheny:ipropyl)-(S)-alanyl]-7-oxa-1-azaspiro[4.4]nonane-2(S)-carboxylic acid;
7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-2-oxa-7-azaspiro[4.4]nonane-6(S)-carboxylic acid;
7-[N-(1-carbomethoxy-3-phenylpropyl)-(S)-alanyl]-2-thia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;

1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-7-thia-1-azaspiro[4.4]nonane-2(S)-carboxylic acid;
7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-2-thia-7-azaspi:ro[4.4]nonane-6(S)-carboxylic acid;
2[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-7-oxa-2-azaspiro[4.5]decane-3(S)-carboxylic acid;
2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-8-oxa-2-azaspiro[4.5]decane-3(S)-carboxylic acid;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-7-oxa-1-lp azaspiro]4.5]decane-2(S)-carboxylic acid;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-8-oxa-1-azaspiro[4.5]decane-2(S)-carboxylic acid;
2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-7-oxa-2 azaspiro[4.5]decane-1(S)-carboxylic acid;
1!~ 2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-8-oxa-2-azaspiro[4.5]decane-1(S)-carboxylic acid;
2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-7-thia-2-azaspiro[4.5]decane-3(S)-carboxylic acid;
2-[N-(1-carbomethoxy-3-phenylpropyl);(S)-alanyl]-8-thia-2-2p azaspiro[4.5]decane-3(S)-carboxylic acid;
1-[IJ-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-7-thia-1-azaspiro[4.5]decane-2(S)-carboxylic acid;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-8-thia-1-azaspiro[4.5]decane-2(S)-carboxylic acid;
25 2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-7-thia-2-azaspiro[4.5]decane-1(S)-carboxylic acid;

2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-8-thia-2-azaspiro[4.5]decane-1(S)-carboxylic acid;
6-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-2-oxa-6-azaspiro[4.5]decane-7(S)-carboxylic acid;
7-[N-(1-carbomethoxy-3-phenylpropyl)-(S)-alanyl]-2-oxa-7-azaspiro[4.5]decane-8(S)-carboxylic acid;
8-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-2-oxa-8-azaspiro[4.5]decane-7(S)-carboxylic acid;
7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-2-oxa-7-azaspiro[4.5]decane-6(S)-carboxylic acid;
7-[N-(1-carboethoxy-3-phenylpropyl)glycyl]-2-thia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
7-[N-(1-carboxy-3-phenylpropyl)glycyl]-2-thia-7-azaspiro-[4.4]nonane-8(S)-carboxylic acid;
2-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-7-oxa-2-azaspiro[4.5]decane-3(S)-carboxylic acid;
2-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-8-oxa-2-azaspiro[4.5]decane-3(S)-carboxylic acid;
1-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-7-oxa-1-azaspiro[4.5]decane-2(S)-carboxylic acid;
6-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-2-thia-6-azaspiro[4.5]decane-7(S)-carboxylic acid;
7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-2-thia-7 azaspiro[4.5]decane-8(S)-carboxylic acid;
8-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-2-thia-8-azaspiro[4.5]decane-7(S)-carboxylic acid;

7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl~-2-thia-7-azaspiro(4.5]decane-6(S)-carboxylic acid;
1-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-8-oxa-1-azaspiro[5.5]undecane-2(S)-carboxylic acid;
1-LN-(1-carboethoxy-3-nhenylpropyl)-(S)-alanyl]-9-oxa-1-azaspiro[5.5]undecane-2(S)-carboxylic acid;
8-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-2-oxa-8-azaspiro[5.5]undecane-9(S)-carboxylic acid;
2-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-9-oxa-2-azaspiro[5.5]undecane-3(S)-carboxylic acid;
9-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-2-oxa-9-azaspiro[5.5]undecane-8(S)-carboxylic acid;
9-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-3-oxa-9-azaspiro[5.5]undecane-8(S)-carboxylic acid;
8-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-2-oxa-8-azaspiro[5.5]undecane-7(S)-carboxylic acid;
8-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-3-oxa-8-azaspiro[5.5)undecane-7(S)-carboxylic acid;
7-[N-(1-carbomethoxy-3-methylthio)-(R,S)-alanyl]-2-thia-7-2U azaspiro[4.4]nonane-8(S)-carboxylic acid;
N-Kl-carboxy-2-benzyloxyethyl)-(S)-alanyl-(S)-proline;
N-(1-carboxy-2-benzylthioethyl)-(S)-alanyl-(S)-proline;
1-[N-(1-carboethoxy-2-benzyloxyethyl)-(S)-alanyl]-octahydroindole-2(S)-carboxylic acid;
1-[N-(1-carboethoxy-2-benzylthioethyl)-(S)-alanyl]-octahydroindole-2(S)-carboxylic acid;

1-[N-(1-carboxy-2-benzyloxyethyl)-(S)-alanyl]octahydro-indole-2(S)-carboxylic acid, 1-[N-(1-carboxy-2-benzylthioethyl)-(S)-alanyl]octahydro-indole-2(S)-carboxylic acid;
7-[N-(1-carboethoxy-2-benzyloxyethyl)-(S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
7-[N-(1-carboethoxy-2-benzylthioethyl)-(S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
1-[N-(1-carboethoxy-2-benzyloxyethyl)-(S)-alanyl]-1~ decahydrocyclohepta[b]pyrrole-2(S)-carboxylic acid;
1-[N-(1-carboethoxy-2-benzylthioethyl)-(S)-alanyl]-decahydrocyclohepta[b]pyrrole-2(S)-carboxylic acid;
N-[1-carboethoxy-2-(4-chlorobenzyloxy)ethyl]-(S)-alanyl-(S)-proline;
1.5 N-[1-carboethoxy-2-(4-chlorobenzylthio)ethyl]-(S)-alanyl-(S)-proline;
1- N-[1-carboethoxy-2-(4-chlorobenzyloxy)ethyl]-(S)-alanyl octahydroindole-2(S)-carboxylic acid;
1- N-[1-carboethoxy-2-(4-chlorobenzylthio)ethyl]-(S)-alanyl octahydroindole-2(S)-carboxylic acid;
1-[N-(1-carbomethoxy-3-phenylpropyl)-(S)-alanyl]-3a(S)~
7a(S)-octahydroindole-2(S)-carboxylic acid;
7- [TT- ( 1 ( S ) -carboethoxy-3-phenylpropy l ) - ( S ) -alanyl ] -1, 4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid;
25 N-[1(S)-carboethoxy-2-benzyloxyethyl]-(S)-alanyl-(S)-proline;

1-[N-(1(S)-carboethoxy-2-benzyloxyethyl)-(S)-alanyl]-3a(S),7a(S)-octahydroindole-2-(S)-carboxylic acid;
1-[N-(1(R)-carboethoxy-2-benzylthioethyl)-(S)-alanyl]-3a(S),7a(S)-octahydroindole-2(S)-carboxylic acid;
N-[1(R)-carboethoxy-2-benzylthioethyl]-(S)-alanyl-(S)-proline ;
1-{N-[1(S)-carboethoxy-3-phenylpro-pyl]-(S)-alanyl)-3a(S), 7a(S)-octahydroindole-2(S)-carboxylic acid.
white crystals, m.p. j°C]:56-60, [a]26=-25.5°
1C> N=[1-(R,S)-(3-phenyl-1-ethoxycarbonyl)propyl]-(S)-alanyl-4,4-ethylenedithio-(S)-proline White solid~mp [°C]: 71-3, [a]D6= -45.2°ethanol N-[1-(R,S)-(3-phenyl-1-methoxycarbonyl)propyl]-(S)-alanyl-octahydroindole-2-carboxylic acid White solid~m.p. [°C]:71 - 73' [a]26=+11.8 (ethanol) N-[1-(R,S)-(3-phenyl-1-methoxycarbonyl)propyl]-(S)-alanyl-octahydroindole-2-carboxylic acid [a]26=-39.0°
7-[~-(3-phenyl-1-ethoxycarbonylpropyl)glycyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid [a]26= - 45.3 (ETON) 1-{~-(1-ethoxycarbonyl-3-phenylpropyl)-(S)-alanylj-cis, syn-octahydroindole-2(S)-carboxylic acid hydrate [a]26=-39.5° (ETON) 1-[~-(1-ethoxycarbonyl-3-phenylpropyl)-(S)-alanyl]-cis,syn-octahydroindole-2(S)-carboxylic acid [a]26=-46.9°
1-~~-[1(R,S)-ethoxycarbonyl-3-phenylpropyl]-(S)-alanyl~-cis-syn-octahydroindole-2(S)-carboxylic acid [a]26=-2.4° (ETOH) 1-[~-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl)-perhydrocyclo-penta[b]pyrrole-2-( )-carboxylic acid [a]26=-5.8° (ETOH) 1-[~-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-perhydro-cyclopenta[b]pyrrole-2-( )-carboxylic acid [a]26--71.3° (lo H20) m.p. 90 -100°C
N-~~~-(S)-ethoxycarbonyl-2-benzyloxyethyl~-(R,S)-alanyl}-(S)-proline hydrochloride hemihydrate ,. [a] 26=-73. 4° (1 o H2O) N-(~-(S)-ethoxycarbonyl-2-thiobenzyloxyethyl)-(R, S)-alanyl-(S)-proline hydrochloride m~P- 121-122°C
1-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-cis,syn-octa-hydroindole-2(S)-carboxylic acid orange solids m.p. [°C] :124 N-(1-(R)-ethoxycarbonyl-2-thiobenzyloxy ethyl)-(R, S)-alanyl-cis-syn-octahydroindole-2-(S)-carboxylic acid hydrochloride dihydrate colorless oil -1-tN-[1-(S)-ethoxycarbonyl~3-phenylpropyl]-(S)-alanyl}~cis, syn-octahydroindole-2-(S)-carboxylic acid benzyl ester 1-[N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-(S)-alanyl}-cis-syn-octahydroindole-2-(S)-carboxylic acid ethyl ester hydro-chloride hemihydrate yellow solid,m.p. [°C]: 55-60 N-(1-(R)-ethoxycarbonyl-2-(4-methylthiobenzyloxy)-ethyl)-(R, S)-alanyl-cis, syn-octahydroindole-2-(S)-carboxylic acid white solid, m.p. [°C]: 148-150, [a]p26--39.3° (H20) 1-(N-[1(S)-carboxy-3-phenylpropyl]-(5)-alanyl}cis,syn-octahydroindole-2(S)-carboxylic acid hydrate colorless oil;
r1-~N-[1(S)-ethoxycarbonyl-3-phenylpropyl~-(S)-alanyl}-1-azacyclooctane-2(R,S)-carboxylic acid benzyl ester off white foam, [a]D6=+16.4° (ETON) 1-~N- [ 1 (S ) -ethoxycarbonyl-3-phenylpropyl~ - (S ) -alanyl~ 1-azacyclooctane-2(R,S)-carboxylic acid hydrate colorless oil, [a]26=-44.7°
1-~N-[1(R)-ethoxycarbonyl-3-phenylpropyl]-(S)-alanyl~cis, syn-octahydroindole-2(S)-carboxylic acid benzyl ester - 9~ - 134120 6 oaf white foam, [a]26= -42.5° (ETOH) 1-[r:~-[1( )-ethoxycaDbonyl-2-phenylpropyl]-(S)-lysyl]cis,syn-octahydroindole-2(S)-carboxylic acid hydrate (diaste=eomer a) off white foam, [a]D6= -36.4°
i--- [rda- [1 ( )-ethoxycarbonyl-3-phenylpropyl]- (S)-lysyl] cis, s_~r_-octahyc~roindole-2 (S)-carboxylic acid (diastereomer b) The following examples describe in detail com-position that are illustrative of the present invention.
It will be apparent to those skilled in the art that many riodifications, both of materials and methods, may be prac-ticed without departing from the purpose and intent of this disclosure.
In the following examples, the active ingredient is 1-~N-[1(S)-carboethoxy-3-phenylpropyl]-(S)-alanyl,}-3a(S), 7a(S)-octahydroindole-2(S)-carboxylic acid.

14120 fi Formulation 1 Capsule Amount (mg) Active ingredient 250.0 125.0 Lactose 173.0 86.5 Corn Starch 75.0 37.5 hta~nesium Stearate 2.0 1.0 500.0 250.0 Blend the active ingredient, lactose and corn starch until uniform; then blend the magnesium stearate :LO into the resulting powder. Encapsulate the mixture into suitably sized tow-piece hard gelatin capsules.
Formulation 2 Tablet Amount (mg) Active ingredient 250.0 125.0 161.0 80.5 Lactose Corn Starch 12.0 6.0 :7ater (per thousand tablets) 120 ml 60 ml (evaporates) (evaporates) Corn Starch 75.0 37.5 Magnesium Stearate 2.0 1.0 500.0 250.0 Blend the active ingredient with the lactose until uniform. Blend the smaller quantity of corn starch with the ~~~uter and add the resulting corn starch paste, then mix un-til a uniform wet mass is formed. Add the remaining corn starch to the remaining wet mass and mix until uniform granules are obtained. Screen the granules through a suit-able milling machine, using a 3/4 inch stainless steel screen. Dry the milled granules in a suitable drying oven until the desired moisture content is obtained. Mill the dried granules through a suitable milling machine using a 16 mesh stainless steel screen. Blend in the magnesium stearate and compress the resulting mixture into tablets of desired shape, thickness, hardness and disintegration.
Formulation 3 Injectable Solution mg/ml Active ingredient 5.00 Methyl-p-hydroxybenzoate 0.80 Propyl-~-hydroxybenzoate 0.10 Disodium Edetate 0.10 Citric Acid Monohydrate 0.08 Dextrose 40.0 Water for injection qs. ad. 1.0 ml Dissolve the ~-hydroxybenzoates in a portion of water for injection at 60-70°C and cool the solution to 25-35°C. Charge and dissolve all other excipients and the active ingredient. Bring the solution to final volume, fil-ter it through a sterilizing membrane and fill into sterile containers.

- loo -Following the procedures of formulation 1, 2 and 3, substitute 1-[N-(1-carbomethoxy-3-phenylpropyl)-(S)-alanyl]octahydroindole-2(S)-carboxylic acid; 1-[N-(1-carboxy-3-l:henylpropyl)-(S)-alanyl]octahydroindole-2(S)-carboxylic aci~3; N-[1(S)-carboethoxy-2-benzyloxyethyl]-(S)-alanyl-(S)-proline; or N-[1(R)-carboethoxy-2-benzylthioethyl]-(S)-alanyl-proline or other compounds of the present invention for 1-;r:-1 (S)-carboethoxy-3-phenylpropyl]- (S)-alanyl~-3a (S) , 7~-~(S)-octahydroindole-2(S)-carboxylic acid to prepare other co=nnositions of the present, invention.

Claims (13)

1. Compounds having the general formula:

wherein:

Y is selected from:

wherein R4 is selected from hydrogen and C1-4 alkyl R1 is selected from:

C1-4 alkyl which may be substituted with amino;
R2 is selected from:

hydrogen; and C1-4 alkyl;

R3 is selected from:

phenyl - C1-3 alkyl; and (CH2)1-2 - X - C1-4 alkyl wherein X is S or NH
and their pharmaceutically acceptable salts.
2. Compounds having the general formula:

wherein:

Y is selected from:

wherein R4 is selected from hydrogen and C1-4 alkyl R1 is selected from:

C1-4 alkyl which may be substituted with amino;
R2 is selected from:

hydrogen; and C1-4 alkyl;

R3 is selected from:
C1-9 alkyl;

phenyl - C1-3 alkyl; and (CH2)1-2 - X - C1-4 alkyl wherein X is S or NH
and their pharmaceutically acceptable salts.
3. Compounds having the general formula:

wherein:
Y is selected from:

R1 is selected from:

C1-4 alkyl which may be substituted with amino;
R2 is selected from:

hydrogen; and C1-2 alkyl;

R3 is selected from:

phenyl - C1-3 alkyl;

and their pharmaceutically acceptable salts.
4. Compounds having the general formula:

wherein:

n is selected from 0 and 1;
R1 is selected from:

C1-4 alkyl which may be substituted with amino;
R2 is selected from:

hydrogen; and C1-4 alkyl;

R3 is selected from:

phenyl - C1-3 alkyl; and (CH2)1-2 - X - C1-4 alkyl wherein X is S or NH
and their pharmaceutically acceptable salts.
5. Compounds having the general formula:

wherein:
n is selected from 1 and 2;
R1 is selected from:

C1-4 alkyl which may be substituted with amino;
R2 is selected from:

hydrogen; and C1-4 alkyl;

R3 is selected from:

phenyl - C1-3 alkyl; and (CH2)1-2 - X - C1-4 alkyl wherein X is S or NH
and their pharmaceutically acceptable salts.
6. Compounds having the general formula:

wherein:
R1 is selected from:
C1-4 alkyl;

R2 is selected from:
hydrogen and C1-4 alkyl;
R4 is selected from:

hydrogen and C1-4 alkyl;

and their pharmaceutically acceptable salts.
7. Compounds having the general formula:

wherein R4 and R6, independently, represent a group selected from hydrogen, and straight and branched chain alkyl of from 1 to 4 carbon atoms, and R5 represents a group selected from straight and branched chain alkyl of from 1 to 4 carbon atoms; and their pharmaceutically acceptable salts thereof.
8. The compound 1-[2-[(1-carboethoxy-3-phenylpropyl)amino]-1- oxopropyl]-octahydro-1H-indole-2-carboxylic acid and its pharmaceutically acceptable salts thereof.
9. The compound 1-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-octahydro-1H-indole-2-carboxylic acid and its pharmaceutically acceptable salts thereof.
10. The compound 7-[N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid and its pharmaceutically acceptable salts thereof.
11. The compound 7-(N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]-1,4-dithia-7-azasspiro[4.4]nonane-8(S)-carboxylic acid and its pharmaceutically acceptable salts thereof.
12. The compound 1-(N-(1-carboethoxy-3-phenylpropyl)-(S)-alanyl]octahydrocyclopenta[b]pyrrole-2(S)-carboxylic acid and its pharmaceutically acceptable salts thereof.
13. The compound 1-[N-(1-carboxy-3-phenylpropyl)-(S)-alanyl]octahydrocyclopenta[b]pyrrole-2(S)-carboxylic acid and its pharmaceutically acceptable salts thereof.
CA000388336A 1980-10-23 1981-10-20 Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them Expired - Fee Related CA1341206C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19988680A 1980-10-23 1980-10-23
US199,886 1980-10-23
US25848481A 1981-04-28 1981-04-28
US258,484 1981-04-28

Publications (1)

Publication Number Publication Date
CA1341206C true CA1341206C (en) 2001-03-20

Family

ID=26895254

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000388336A Expired - Fee Related CA1341206C (en) 1980-10-23 1981-10-20 Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them

Country Status (28)

Country Link
US (2) US4818749A (en)
EP (1) EP0050800B2 (en)
JP (1) JPH01163197A (en)
KR (1) KR880001843B1 (en)
AT (1) ATE20469T1 (en)
AU (1) AU554362B2 (en)
CA (1) CA1341206C (en)
CY (1) CY1469A (en)
DE (2) DE19575012I2 (en)
DK (1) DK161523C (en)
ES (1) ES506414A0 (en)
FI (1) FI83222C (en)
GR (1) GR75059B (en)
HK (1) HK36189A (en)
HU (1) HU193146B (en)
IE (1) IE53802B1 (en)
IL (1) IL64085A (en)
KE (1) KE3845A (en)
LU (1) LU88621I2 (en)
MA (1) MA19309A1 (en)
MY (1) MY8700683A (en)
NL (1) NL940001I2 (en)
NO (2) NO164983C (en)
NZ (1) NZ198702A (en)
OA (1) OA06929A (en)
PH (1) PH21916A (en)
PT (1) PT73861B (en)
SG (1) SG78188G (en)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595675A (en) * 1979-09-19 1986-06-17 Hoechst Aktiengesellschaft Bicyclic α-iminocarboxylic acid compounds having hypotensive activity
US4616030A (en) * 1979-12-07 1986-10-07 Adir Perhydroindole-2-carboxylic acids as antihypertensives
US4508729A (en) * 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
US4616031A (en) * 1979-12-07 1986-10-07 Adir Perhydroindole-2-carboxylic acids as antihypertensives
US4644008A (en) * 1979-12-07 1987-02-17 Adir Perhydroindole-2-carboxylic acids as antihypertensives
US4616029A (en) * 1979-12-07 1986-10-07 Adir Perhydromdole-2-carboxylic acids as antihypertensives
US4350704A (en) * 1980-10-06 1982-09-21 Warner-Lambert Company Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids
DE3177130D1 (en) * 1980-08-30 1990-01-11 Hoechst Ag AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEANS CONTAINING THEM AND THE USE THEREOF.
DE19575012I2 (en) * 1980-10-23 2002-01-24 Schering Corp Carboxyalkyl dipeptides Process for their preparation and medicaments containing them
US4610816A (en) * 1980-12-18 1986-09-09 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
US4906615A (en) * 1980-12-18 1990-03-06 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
DE3260423D1 (en) * 1981-02-17 1984-08-30 Warner Lambert Co Substituted acyl derivatives of octahydro-1h-isoindole-1-carboxylic acids and esters
US4496542A (en) * 1981-03-30 1985-01-29 Usv Pharmaceutical Corporation N-substituted-amido-amino acids
US4766110A (en) * 1981-08-21 1988-08-23 Ryan James W Novel complex amido and imido derivatives of carboxyalkyl peptides
DE3226768A1 (en) * 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt DERIVATIVES OF CIS, ENDO-2-AZABICYCLO- (3.3.0) -OCTAN-3-CARBONIC ACID, METHOD FOR THE PRODUCTION THEREOF, THE MEANS CONTAINING THEM AND THE USE THEREOF
EP0081094A1 (en) * 1981-11-12 1983-06-15 Merck & Co. Inc. Substituted omega-amino-carboxymethyldipeptide antihypertensive agents
US4503043A (en) * 1981-12-07 1985-03-05 Warner-Lambert Company Substituted acyl derivatives of octahydro-1H-isoindole-1-carboxylic acids
CA1341296C (en) * 1981-12-29 2001-09-25 Hansjorg Urbach 2-azabicycloalkane-3-carboxylic acid derivatives, processes for their preparation, agents containing these compounds and their use
ATE25244T1 (en) * 1981-12-29 1987-02-15 Hoechst Ag NEW DERIVATIVES OF BICYCLIC AMINO ACIDS, PROCESS FOR THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND THEIR USE, AS WELL AS NEW BICYCLIC AMINO ACIDS AS INTERMEDIATE STAGES AND PROCESS FOR THEIR PREPARATION.
DE3360065D1 (en) * 1982-03-08 1985-03-28 Schering Corp Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them
DE3211397A1 (en) * 1982-03-27 1983-11-10 Hoechst Ag, 6230 Frankfurt SPIRO (4. (3 + N)) - 2-AZA-3-CARBONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THE MEANS CONTAINING THEM AND THEIR USE
DE3211676A1 (en) * 1982-03-30 1983-10-06 Hoechst Ag NEW DERIVATIVES OF CYCLOALKA (C) PYRROL CARBONIC ACIDS, METHOD FOR THE PRODUCTION THEREOF, THEIR SUBSTANCES AND THE USE THEREOF AND NEW CYCLOALKA (C) PYRROL CARBONIC ACIDS AS THE INTERMEDIATE LEVELS AND METHODS
US4555503A (en) * 1982-05-05 1985-11-26 Merck & Co., Inc. N2 -(Substituted)carboxymethyl-N6 -(substituted)-lysyl-and αε-aminoalkyl)glycyl amino acid antihypertensive agents
US4483850A (en) * 1982-05-10 1984-11-20 Merck & Co., Inc. N-Terminal substituted oligopeptide converting enzyme inhibitors
DE3218540A1 (en) * 1982-05-17 1983-11-24 Hoechst Ag, 6230 Frankfurt SPIRO-2-AZA-ALKAN-3-CARBONITRILE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
DE3376649D1 (en) * 1982-06-17 1988-06-23 Schering Corp Substituted dipeptides, methods for their production, pharmaceutical compositions containing them, method for making such pharmaceutical compositions
AU1643283A (en) * 1982-07-19 1984-01-26 E.R. Squibb & Sons, Inc. Substituted peptides
US4470973A (en) * 1982-07-19 1984-09-11 E. R. Squibb & Sons, Inc. Substituted peptide compounds
US4500713A (en) * 1982-09-23 1985-02-19 Usv Pharmaceutical Corporation Therapeutic dipeptides
US4634716A (en) * 1982-09-30 1987-01-06 Merck & Co., Inc. Substituted N-carboxymethyl-aminoacylaminoalkanoic acids useful as antihypertensive agents
DE3242151A1 (en) * 1982-11-13 1984-05-17 Hoechst Ag, 6230 Frankfurt NEW DERIVATIVES OF TRICYCLIC AMINO ACIDS, METHOD FOR THE PRODUCTION THEREOF, THEIR SUBSTANCES AND THE USE THEREOF, AND NEW BICYCLIC AMINO ACIDS AS INTERMEDIATE STAGES AND METHOD FOR THE PRODUCTION THEREOF
US4499079A (en) * 1982-11-18 1985-02-12 E. R. Squibb & Sons, Inc. Carboxy and substituted carboxy alkanoyl and cycloalkanoyl peptides
US4642315A (en) * 1982-11-18 1987-02-10 E. R. Squibb & Sons, Inc. Carboxy and substituted carboxy alkanoyl and cycloalkanoyl peptides
US4587234A (en) * 1982-11-18 1986-05-06 E. R. Squibb & Sons, Inc. Carboxy and substituted carboxy alkanoyl and cycloalkanoyl peptides
DE3246503A1 (en) * 1982-12-16 1984-06-20 Hoechst Ag, 6230 Frankfurt DERIVATIVES OF CIS, ENDO-2-AZABICYCLO- (5.3.0) -DECAN-3-CARBONIC ACID, METHOD FOR THE PRODUCTION THEREOF, THESE AGENTS AND THE USE THEREOF
US4826812A (en) * 1982-12-27 1989-05-02 Schering Corporation Antiglaucoma agent
DE3381850D1 (en) * 1982-12-27 1990-10-04 Schering Corp PHARMACEUTICAL COMPOSITION.
DE3300774A1 (en) * 1983-01-12 1984-07-12 Hoechst Ag, 6230 Frankfurt NEW SPIROCYCLIC AMINO ACIDS, METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF AND NEW SPIROCYCLIC AMINO ACIDS AS INTERMEDIATE PRODUCTS AND METHOD FOR THE PRODUCTION THEREOF
DE3302125A1 (en) * 1983-01-22 1984-07-26 Boehringer Ingelheim KG, 6507 Ingelheim AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF
US5175306A (en) * 1983-01-31 1992-12-29 Hoechst Aktiengesellschaft Process for the resolution of racemates of optically active bicyclic imino-α-carboxylic esters
DE3303344A1 (en) 1983-02-02 1984-08-02 Hoechst Ag, 6230 Frankfurt METHOD FOR PRODUCING N-ALKYLATED AMINO ACIDS AND THEIR ESTERS
US4596791A (en) * 1983-03-16 1986-06-24 Usv Pharmaceutical Corp. Compounds for treating hypertension
DK156484A (en) * 1983-03-16 1984-09-17 Usv Pharma Corp AMINO ACID DERIVATIVES
US4666906A (en) * 1983-03-16 1987-05-19 Usv Pharmaceutical Corporation Compounds for treating hypertension
GB8311286D0 (en) * 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
US4585758A (en) * 1983-05-20 1986-04-29 Usv Pharmaceutical Corp. Angiotensin-converting enzyme inhibitors
US4584285A (en) * 1983-06-02 1986-04-22 Schering Corporation Antihypertensive agents
US4783444A (en) * 1984-09-17 1988-11-08 Schering Corporation Antiglaucoma compositions and methods
FR2546886B2 (en) * 1983-06-06 1986-05-16 Adir DERIVATIVES OF ISOINDOLEDICARBOXYLIC ACIDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE3322530A1 (en) * 1983-06-23 1985-01-10 Hoechst Ag, 6230 Frankfurt METHOD FOR PRODUCING MONO, BI AND TRICYCLIC AMINO ACIDS
US4514391A (en) * 1983-07-21 1985-04-30 E. R. Squibb & Sons, Inc. Hydroxy substituted peptide compounds
DE3333455A1 (en) * 1983-09-16 1985-04-11 Hoechst Ag, 6230 Frankfurt METHOD FOR PRODUCING N-ALKYLATED DIPEPTIDES AND THEIR ESTERS
DE3333454A1 (en) * 1983-09-16 1985-04-11 Hoechst Ag, 6230 Frankfurt METHOD FOR PRODUCING N-ALKYLATED DIPEPTIDES AND THEIR ESTERS
US4642355A (en) * 1984-02-24 1987-02-10 Otsuka Pharmaceutical Factory, Inc. Proline derivatives
US4555508A (en) * 1984-03-02 1985-11-26 Usv Pharmaceutical Corp. Antihypertensive spiro-cyclic compounds
US4556652A (en) * 1984-03-02 1985-12-03 Usv Pharmaceutical Corp. Antihypertensive spiro-amidoamino compounds
DE3408923A1 (en) * 1984-03-12 1985-09-26 Hoechst Ag, 6230 Frankfurt CARBOXYALKYLDIPEPTIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THE AGENTS CONTAINING THEM AND THE USE THEREOF
US5684016A (en) * 1984-04-12 1997-11-04 Hoechst Aktiengesellschaft Method of treating cardiac insufficiency
DE3413710A1 (en) * 1984-04-12 1985-10-24 Hoechst Ag, 6230 Frankfurt METHOD FOR TREATING HEART INSUFFICIENCY
US4500518A (en) * 1984-04-19 1985-02-19 E. R. Squibb & Sons, Inc. Amino thiol dipeptides
US4558150A (en) * 1984-04-19 1985-12-10 E. R. Squibb & Sons, Inc. Intermediates for preparing amino thiol dipeptides
AU569789B2 (en) * 1984-05-03 1988-02-18 Brigham And Women's Hospital A.c.e. inhibitors to treat renal diseases
EP0190224A1 (en) * 1984-07-30 1986-08-13 Schering Corporation PROCESS FOR THE PREPARATION OF CIS, ENDOOCTAHYDROCYCLOPENTA [b] PYRROLE-2-CARBOXYLATE
DE3431541A1 (en) * 1984-08-28 1986-03-06 Hoechst Ag, 6230 Frankfurt CIS, ENDO-2-AZABICYCLOALKAN-3-CARBONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND INTERMEDIATE PRODUCTS IN THEIR PRODUCTION
IT1176983B (en) * 1984-10-16 1987-08-26 Zambon Spa DIPEPTIDES WITH PHARMACOLOGICAL ACTIVITY
EP0187037A3 (en) * 1984-12-21 1988-03-23 Takeda Chemical Industries, Ltd. Piperidine derivatives, their production and use
CS250699B2 (en) * 1984-12-21 1987-05-14 Pfizer Method of octahydro-6-azaindole's depetidic derivatives production
US4762821A (en) * 1985-03-22 1988-08-09 Syntex (U.S.A.) Inc. N',N"-dialkylguanidino dipeptides
DE3529960A1 (en) * 1985-08-22 1987-03-05 Boehringer Ingelheim Kg AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF
US5231080A (en) * 1985-10-15 1993-07-27 Hoechst Aktiengesellschaft Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
US4886813A (en) * 1985-11-13 1989-12-12 Otsuka Pharmaceutical Factory, Inc. Proline derivatives
JPH0662671B2 (en) * 1986-01-17 1994-08-17 株式会社大塚製薬工場 Proline derivative
US5231084A (en) * 1986-03-27 1993-07-27 Hoechst Aktiengesellschaft Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons
DE3610391A1 (en) * 1986-03-27 1987-10-08 Hoechst Ag COMPOUNDS WITH NOOTROPPER ACTION, THESE CONTAINERS AND THEIR USE IN THE TREATMENT AND PROPHYLAXIS OF COGNITIVE DYSFUNCTIONS
EP0254032A3 (en) * 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
EP0566157A1 (en) 1986-06-20 1993-10-20 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
US5948939A (en) * 1986-09-10 1999-09-07 Syntex (U.S.A.) Inc. Selective amidination of diamines
JP2579323B2 (en) * 1986-09-10 1997-02-05 シンテックス（ユー・エス・エイ）インコーポレイテッド Selective amidine formation of diamines
DE3633496A1 (en) * 1986-10-02 1988-04-14 Hoechst Ag COMBINATION OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS WITH CALCIUMANTAGONISTS AND THEIR USE IN MEDICINAL PRODUCTS
DE3639879A1 (en) * 1986-11-21 1988-06-01 Hoechst Ag METHOD FOR PRODUCING MONO, BI AND TRICYCLIC AMINO ACIDS, INTERMEDIATE PRODUCTS OF THIS METHOD, AND A METHOD FOR PRODUCING THE SAME
DE3641451A1 (en) * 1986-12-04 1988-06-16 Hoechst Ag DERIVATIVES OF BICYCLIC AMINOCARBONIC ACIDS, METHODS AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION AND USE THEREOF
US5262436A (en) * 1987-03-27 1993-11-16 Schering Corporation Acylamino acid antihypertensives in the treatment of congestive heart failure
DE3722007A1 (en) * 1987-07-03 1989-01-12 Hoechst Ag METHOD FOR PRODUCING BICYCLIC AMINOCARBONIC ACIDS, INTERMEDIATE PRODUCTS OF THIS METHOD AND THE USE THEREOF
DE3739690A1 (en) * 1987-11-24 1989-06-08 Hoechst Ag STABILIZED MEDICINAL PRODUCTS, METHOD FOR THEIR PRODUCTION AND STABLE MEDICAL PREPARATIONS
DE3801587A1 (en) * 1988-01-21 1989-08-03 Hoechst Ag NEW AMINO ACID GLYCERIDES, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THEM AND THE USE THEREOF
DE3803225A1 (en) * 1988-02-04 1989-08-17 Hoechst Ag AMINO ACID AMIDE WITH PSYCHOTROPIC EFFECT, METHOD FOR THE PRODUCTION THEREOF, AGENTS CONTAINING THE SAME AND THEIR USE
HU904967D0 (en) * 1988-04-22 1991-01-28 Hoechst Ag Process for producing new azabicyclo(3.3.o)octane-3-carboxylic acid-octylesther derivatives
DD284030A5 (en) 1988-11-24 1990-10-31 Hoechst Ag,De PROCESS FOR THE PREPARATION OF PEPTIDES WITH BRADYKININ-ANTAGONISTIC EFFECT
ZA902661B (en) * 1989-04-10 1991-01-30 Schering Corp Mercapto-acyl amino acids
US5389610A (en) * 1989-11-21 1995-02-14 Schering Corporation Carboxyalkylcarbonyl aminoacid endopeptidase inhibitors
US5075302A (en) * 1990-03-09 1991-12-24 Schering Corporation Mercaptoacyl aminolactam endopeptidase inhibitors
US5173506A (en) * 1990-08-16 1992-12-22 Schering Corporation N-(mercaptoalkyl)ureas and carbamates
US5225401A (en) * 1991-08-12 1993-07-06 E. R. Squibb & Sons, Inc. Treatment of congestive heart failure
LT3872B (en) 1993-12-06 1996-04-25 Hoechst Ag Novel peptides and pharmaceutical compositions containing them
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US20020042377A1 (en) * 1995-06-07 2002-04-11 Steiner Joseph P. Rotamase enzyme activity inhibitors
US7056935B2 (en) 1995-06-07 2006-06-06 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5801197A (en) * 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
ES2171768T3 (en) 1996-03-20 2002-09-16 Hoechst Ag OSEA RESORTION INHIBITORS AND VITRONECTINE RECEPTORS ANTAGONISTS.
FR2746394B1 (en) 1996-03-20 1998-05-29 Roussel Uclaf NOVEL TRICYCLIC COMPOUNDS, THEIR PREPARATION PROCESS, AND INTERMEDIATES THEREOF, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5801187A (en) * 1996-09-25 1998-09-01 Gpi-Nil Holdings, Inc. Heterocyclic esters and amides
US5786378A (en) * 1996-09-25 1998-07-28 Gpi Nil Holdings, Inc. Heterocyclic thioesters
US6218424B1 (en) * 1996-09-25 2001-04-17 Gpi Nil Holdings, Inc. Heterocyclic ketone and thioester compounds and uses
DE19653647A1 (en) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin receptor antagonists, their preparation and their use
US6274602B1 (en) * 1998-06-03 2001-08-14 Gpi Nil Holdings, Inc. Heterocyclic thioester and ketone hair growth compositions and uses
US6271244B1 (en) 1998-06-03 2001-08-07 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses
US5945441A (en) 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
US6187784B1 (en) 1998-06-03 2001-02-13 Gpi Nil Holdings, Inc. Pipecolic acid derivative hair growth compositions and uses
US6187796B1 (en) 1998-06-03 2001-02-13 Gpi Nil Holdings, Inc. Sulfone hair growth compositions and uses
US20010049381A1 (en) 1997-06-04 2001-12-06 Gpl Nil Holdings, Inc., Pyrrolidine derivative hair growth compositions and uses
DE19741235A1 (en) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Novel imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them
DE19741873A1 (en) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh New 5-ring heterocycles, their preparation, their use and pharmaceutical preparations containing them
DE19751251A1 (en) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituted imidazolidine derivatives, their manufacture, their use and pharmaceutical preparations containing them
DE19821483A1 (en) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh New imidazolidine derivatives useful as leukocyte adhesion and migration inhibitors and/or VLA-4 receptor antagonists for treating E.G. inflammatory and allergic disorders
US6172087B1 (en) 1998-06-03 2001-01-09 Gpi Nil Holding, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
WO1999062487A1 (en) * 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. Heterocyclic ester and amide hair growth compositions and uses
US6429215B1 (en) 1998-06-03 2002-08-06 Gpi Nil Holdings, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6395758B1 (en) 1998-08-14 2002-05-28 Gpi Nil Holdings, Inc. Small molecule carbamates or ureas for vision and memory disorders
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US6506788B1 (en) 1998-08-14 2003-01-14 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US6335348B1 (en) 1998-08-14 2002-01-01 Gpi Nil Holdings, Inc. Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US6333340B1 (en) 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6462072B1 (en) 1998-09-21 2002-10-08 Gpi Nil Holdings, Inc. Cyclic ester or amide derivatives
AR036187A1 (en) * 2001-07-24 2004-08-18 Adir A PROCESS FOR THE PREPARATION OF PERINDOPRIL, ANALOG COMPOUNDS AND ITS SALTS, INTERMEDIARY COMPOUND 2,5-DIOXO-OXAZOLIDINE AND PROCESS TO PREPARE A INTERMEDIARY
US6407262B1 (en) 2001-11-21 2002-06-18 Brantford Chemicals Inc. Process for the preparation of Ramipril
BR0308118A (en) * 2002-03-01 2005-01-11 Warner Lambert Co Method For Treating Osteoarthritis
BRPI0409560A (en) * 2003-04-15 2006-04-18 Warner Lambert Co [b] -condensed bicyclic proline derivatives and their use to treat arthritic conditions
CA2521364A1 (en) * 2003-04-15 2004-10-28 Warner-Lambert Company Llc [c]-fused bicyclic proline derivatives and their use for treating arthritic conditions
EP1817007A2 (en) * 2004-11-05 2007-08-15 King Pharmaceuticals Research and Development Inc. Stabilized individually coated ramipril particles, compositions and methods
DE602005009918D1 (en) * 2005-01-06 2008-11-06 Ipca Lab Ltd Process for the synthesis of (2S, 3aS, 7aS) -1- (S) -alanyl-octahydro-1H-2-carboxylic acid derivatives and use in the synthesis of perindopril
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
EP2481737A1 (en) * 2008-06-24 2012-08-01 Merck Sharp & Dohme Corp. Biocatalytic processes for the preparation of substantially stereomerically pure fused bicyclic proline compounds
WO2013121233A1 (en) 2012-02-17 2013-08-22 Egis Gyógyszergyár Nyilvánosan Működö Részvénytársaság Pharmaceutical formulation having improved stability
HUP1300496A2 (en) 2013-08-16 2015-03-02 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Stable pharmaceutical composition
WO2015033781A1 (en) 2013-09-03 2015-03-12 長瀬産業株式会社 Method for producing dipeptide derivative containing disubstituted amino acid residue

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
FR2503155A2 (en) * 1980-10-02 1982-10-08 Science Union & Cie NOVEL SUBSTITUTED IMINO DIACIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS AN ENZYME INHIBITOR
US4508729A (en) * 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
ZA811493B (en) * 1980-04-02 1982-03-31 Warner Lambert Co Substituted acyl derivatives of octahydro-1h-indole-2-carboxylic acids
IE52663B1 (en) * 1980-04-02 1988-01-20 Warner Lambert Co Substituted acyl derivatives of octahydro-1h-indole-2-carboxylic acids
US4350704A (en) * 1980-10-06 1982-09-21 Warner-Lambert Company Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids
DE3177130D1 (en) * 1980-08-30 1990-01-11 Hoechst Ag AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEANS CONTAINING THEM AND THE USE THEREOF.
ZA816292B (en) * 1980-09-17 1983-01-26 Univ Miami Carboxyalkyl peptides and thioethers and ethers of peptides as antihypertensive agents
JPS5793943A (en) * 1980-10-06 1982-06-11 Merck & Co Inc Antihypertensive dipeptide derivative
FR2492381A1 (en) * 1980-10-21 1982-04-23 Science Union & Cie NOVEL AZA BICYCLO ALKANE CARBOXYLIC ACIDS SUBSTITUTED IN THEIR PREPARATION METHODS AND THEIR USE AS AN ENZYME INHIBITOR
DE19575012I2 (en) * 1980-10-23 2002-01-24 Schering Corp Carboxyalkyl dipeptides Process for their preparation and medicaments containing them
DE3226768A1 (en) * 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt DERIVATIVES OF CIS, ENDO-2-AZABICYCLO- (3.3.0) -OCTAN-3-CARBONIC ACID, METHOD FOR THE PRODUCTION THEREOF, THE MEANS CONTAINING THEM AND THE USE THEREOF
CA1341296C (en) * 1981-12-29 2001-09-25 Hansjorg Urbach 2-azabicycloalkane-3-carboxylic acid derivatives, processes for their preparation, agents containing these compounds and their use

Also Published As

Publication number Publication date
PT73861A (en) 1981-11-01
IL64085A (en) 1986-12-31
EP0050800B2 (en) 1995-06-07
MA19309A1 (en) 1982-07-01
ATE20469T1 (en) 1986-07-15
NL940001I1 (en) 1994-03-01
NL940001I2 (en) 1998-03-02
DE3174844D1 (en) 1986-07-24
NO164983C (en) 1990-12-05
ES8308838A1 (en) 1983-10-01
IE53802B1 (en) 1989-03-01
KE3845A (en) 1989-04-07
PH21916A (en) 1988-04-08
AU7661481A (en) 1982-04-29
DK161523B (en) 1991-07-15
DK161523C (en) 1991-12-23
HK36189A (en) 1989-05-12
DK462581A (en) 1982-04-24
IE812475L (en) 1982-04-23
PT73861B (en) 1985-11-12
LU88621I2 (en) 1995-09-01
JPH01163197A (en) 1989-06-27
FI83222B (en) 1991-02-28
NZ198702A (en) 1985-08-30
NO164983B (en) 1990-08-27
KR880001843B1 (en) 1988-09-21
EP0050800A1 (en) 1982-05-05
ES506414A0 (en) 1983-10-01
FI813283L (en) 1982-04-24
FI83222C (en) 1991-06-10
KR830007519A (en) 1983-10-21
SG78188G (en) 1989-03-23
EP0050800B1 (en) 1986-06-18
NO813546L (en) 1982-04-26
OA06929A (en) 1983-05-31
US4818749A (en) 1989-04-04
CY1469A (en) 1989-07-21
MY8700683A (en) 1987-12-31
NO1995008I1 (en) 1995-09-22
AU554362B2 (en) 1986-08-21
HU193146B (en) 1987-08-28
US4831157A (en) 1989-05-16
DE19575012I2 (en) 2002-01-24
GR75059B (en) 1984-07-13

Similar Documents

Publication Publication Date Title
CA1341206C (en) Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them
EP0088350B1 (en) Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them
US4410520A (en) 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
EP0012401B1 (en) Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them
US4587258A (en) Angiotensin-converting enzyme inhibitors
US4562202A (en) N-Acyl hexahydroindole-2-carboxylic acids and anti-hypertensive use thereof
US4473575A (en) 3-Amino-(1)-benzazepin-2-one-1-alkanoic acids
US4470972A (en) 7-Carboxyalkylaminoacyl-1,4-dithia-7-azaspiro[4.4]-nonane-8-carboxylic acids
US4626545A (en) Amino acid derivatives as enzyme inhibitors
EP0046291B1 (en) Substituted caprolactam derivatives as antihypertensives, process for preparing them, pharmaceutical composition containing them, and intermediates
US4575503A (en) 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
CA1263000A1 (en) Derivatives of 2-azabicyclo[3.1.0]hexane-3- carboxylic acid, a process for their preparation, agents containing them and their use; and 2- azabicyclo[3.1.0]hexane derivatives as intermediates, and a process for their preparation
CY1403A (en) Benzazepin-2-ones
HU185324B (en) Process for preparing 1-carboxy-azaalkanoyl-indoline-2-carboxylic acid derivatives
US4826855A (en) Thieno pyridines and their use as anti-hypertensive agents
AU594969B2 (en) Amino acid derivatives
US4629787A (en) Substituted caprolactam derivatives as antihypertensives
US4680392A (en) Substituted caprolactam derivatives as antihypertensives
US5348944A (en) Carboxyalkyl dipeptides
EP0049506A1 (en) N-carboxyalkyl dipeptides, a process for preparing and a pharmaceutical composition comprising the same
CZ413891A3 (en) carboxyalkyl dipeptides, processes of their preparation and pharmaceutical compositions in which they are comprised
EP0059966A1 (en) Substituted thiazolidine carboxylic acid analogs and derivatives as antihypertensives

Legal Events

Date Code Title Description
MKLA Lapsed

Effective date: 20150320